Prof. R.F. van Vollenhoven PhD publications

2020

• Fanouriakis Antonis, Kostopoulou Myrto, Cheema Kim, Anders Hans-Joachim, Aringer Martin, Bajema Ingeborg, Boletis John, Frangou Eleni, Houssiau Frederic A., Hollis Jane, Karras Adexandre, Marchiori Francesca, Marks Stephen D., Moroni Gabriella, Mosca Marta, Parodis Ioannis, Praga Manuel, Schneider Matthias, Smolen Josef S., Tesar Vladimir, Trachana Maria, van Vollenhoven Ronald F., Voskuyl Alexandre E., Teng Y. K. Onno, van Leew Bernadette, Bertsias George, Jayne David, Boumpas Dimitrios T. 2019 Update of the Joint European League against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis Annals of the rheumatic diseases 2020;79 (6):S713-S723 [PubMed]
• Urowitz Murray B., Gladman Dafna D., Farewell Vernon, Su Jiandong, Romero-Diaz Juanita, Bae Sang-Cheol, Fortin Paul R., Sanchez-Guerrero Jorge, Clarke Ann Elaine, Bernatsky Sasha, Gordon Caroline, Hanly John G., Wallace Daniel J., Isenberg David A., Rahman Anisur, Merrill Joan T., Ginzler Ellen, Alarcón Graciela S., Chatham W. Winn, Petri Michelle A., Bruce Ian N., Khamashta Munther A., Aranow Cynthia, Dooley Mary Anne, Manzi Susan, Ramsey-Goldman Rosalind, Nived Ola, Jönsen Andreas, Steinsson Kristján, Zoma Asad A., Ruiz-Irastorza Guillermo, Lim S. Sam, Kalunian Kenneth C., Ỉnanç Murat, van Vollenhoven Ronald, Ramos-Casals Manuel, Kamen Diane L., Jacobsen Soren, Peschken Christine A., Askanase Anca, Stoll Thomas Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort Arthritis & rheumatology (Hoboken, N.J.) 2020;72 (10):1734-1740 [PubMed]
• Hetland Merete Lund, Haavardsholm Espen A., Rudin Anna, Nordström Dan, Nurmohamed Michael, Gudbjornsson Bjorn, Lampa Jon, Hørslev-Petersen Kim, Uhlig Till, Grondal Gerdur, Østergaard Mikkel, Heiberg Marte S., Twisk Jos, Lend Kristina, Krabbe Simon, Hyldstrup Lise Hejl, Lindqvist Joakim, Hultgård Ekwall Anna-Karin, Grøn Kathrine Lederballe, Kapetanovic Meliha, Faustini Francesca, Tuompo Riitta, Lorenzen Tove, Cagnotto Giovanni, Baecklund Eva, Hendricks Oliver, Vedder Daisy, Sokka-Isler Tuulikki, Husmark Tomas, Ljoså Maud-Kristine Aga, Brodin Eli, Ellingsen Torkell, Söderbergh Annika, Rizk Milad, Olsson Åsa Reckner, Larsson Per, Uhrenholt Line, Just S. ren Andreas, Stevens David John, Laurberg Trine Bay, Bakland Gunnstein, Olsen Inge C., van Vollenhoven Ronald Active conventional treatment and three different biological treatments in early rheumatoid arthritis: Phase IV investigator initiated, randomised, observer blinded clinical trial BMJ (Clinical research ed.) 2020;371 [PubMed]
• Vanier Antoine, Smolen Josef S., Allaart Cornelia F., van Vollenhoven Ronald, Verschueren Patrick, Vastesaeger Nathan, Saevarsdottir Saedis, Visser Karen, Aletaha Daniel, Combe Bernard, Fautrel Bruno An updated matrix to predict rapid radiographic progression of early rheumatoid arthritis patients: pooled analyses from several databases Rheumatology (Oxford, England) 2020;59 (8):1842-1852 [PubMed]
• Kay Jonathan, Harigai Masayoshi, Rancourt Josh, Dickson Christina, Melby Thomas, Issa Maher, de la Torre Inmaculada, Isaka Yoshitaka, Cardoso Anabela, Saifan Chadi, Keystone Edward C., van Vollenhoven Ronald F., Giles Jon T., Huizinga Tom W. J., Kremer Joel M. Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib RMD open 2020;6 (3) [PubMed]
• Legge Alexandra, Kirkland Susan, Rockwood Kenneth, Andreou Pantelis, Bae Sang-Cheol, Gordon Caroline, Romero-Diaz Juanita, Sanchez-Guerrero Jorge, Wallace Daniel J., Bernatsky Sasha, Clarke Ann E., Merrill Joan T., Ginzler Ellen M., Fortin Paul, Gladman Dafna D., Urowitz Murray B., Bruce Ian N., Isenberg David A., Rahman Anisur, Alarcón Graciela S., Petri Michelle, Khamashta Munther A., Dooley M. A., Ramsey-Goldman Rosalind, Manzi Susan, Zoma Asad A., Aranow Cynthia, Mackay Meggan, Ruiz-Irastorza Guillermo, Lim S. Sam, Inanc Murat, van Vollenhoven Ronald F., Jonsen Andreas, Nived Ola, Ramos-Casals Manuel, Kamen Diane L., Kalunian Kenneth C., Jacobsen Soren, Peschken Christine A., Askanase Anca, Hanly John G. Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus Journal of rheumatology 2020;47 (1):72-81 [PubMed]
• Newling M., Fiechter R. H., Sritharan L., Hoepel W., van Burgsteden J. A., Hak A. E., van Vollenhoven R. F., van de Sande M. G. H., Baeten D. L. P., den Dunnen J. Dysregulated Fcγ receptor IIa-induced cytokine production in dendritic cells of lupus nephritis patients Clinical and experimental immunology 2020;199 (1):39-49 [PubMed]
• Barber Megan R. W., Hanly John G., Su Li, Urowitz Murray B., St. Pierre Yvan, Romero-Diaz Juanita, Gordon Caroline, Bae Sang-Cheol, Bernatsky Sasha, Wallace Daniel J., Merrill Joan T., Isenberg David A., Rahman Anisur, Ginzler Ellen M., Petri Michelle, Bruce Ian N., Dooley Mary A., Fortin Paul R., Gladman Dafna D., Sanchez-Guerrero Jorge, Steinsson Kristjan, Ramsey-Goldman Rosalind, Khamashta Munther A., Aranow Cynthia, Mackay Meggan, Alarcón Graciela S., Manzi Susan, Nived Ola, Jönsen Andreas, Zoma Asad A., van Vollenhoven Ronald F., Ramos-Casals Manuel, Ruiz-Irastorza Guillermo, Lim S. Sam, Kalunian Kenneth C., Inanc Murat, Kamen Diane L., Peschken Christine A., Jacobsen S. ren, Askanase Anca, Farewell Vernon, Stoll Thomas, Buyon Jill, Clarke Ann E. Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach Arthritis care and research 2020;72 (12):1800-1808 [PubMed]
• van Vollenhoven Ronald, Takeuchi Tsutomu, Pangan Aileen L., Friedman Alan, Mohamed Mohamed-Eslam F., Chen Su, Rischmueller Maureen, Blanco Ricardo, Xavier Ricardo M., Strand Vibeke Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator–Controlled Trial Arthritis & rheumatology (Hoboken, N.J.) 2020;72 (10):1607-1620 [PubMed]
• Kerschbaumer Andreas, Sepriano Alexandre, Smolen Josef S., van der Heijde D. sirée, Dougados Maxime, van Vollenhoven Ronald, McInnes Iain B., Bijlsma Johannes W. J., Burmester Gerd R., de Wit Maarten, Falzon Louise, Landewé Robert Efficacy of pharmacological treatment in rheumatoid arthritis: A systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis Annals of the rheumatic diseases 2020;79 (6):S744-S759 [PubMed]
• Smolen Josef S., Landewé Robert B. M., Bijlsma Johannes W. J., Burmester Gerd R., Dougados Maxime, Kerschbaumer Andreas, McInnes Iain B., Sepriano Alexandre, van Vollenhoven Ronald F., de Wit Maarten, Aletaha Daniel, Aringer Martin, Askling John, Balsa Alejandro, Boers Maarten, den Broeder Alfons A., Buch Maya H., Buttgereit Frank, Caporali Roberto, Cardiel Mario Humberto, de Cock Diederik, Codreanu Catalin, Cutolo Maurizio, Edwards Christopher John, van Eijk-Hustings Yvonne, Emery Paul, Finckh Axel, Gossec Laure, Gottenberg Jacques-Eric, Hetland Merete Lund, Huizinga Tom W. J., Koloumas Marios, Li Zhanguo, Mariette Xavier, Müller-Ladner Ulf, Mysler Eduardo F., da Silva Jose A. P., Poór Gyula, Pope Janet E., Rubbert-Roth Andrea, Ruyssen-Witrand Adeline, Saag Kenneth G., Strangfeld Anja, Takeuchi Tsutomu, Voshaar Marieke, Westhovens René, van der Heijde D. sirée EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update Annals of the rheumatic diseases 2020;79 (6):S685-S699 [PubMed]
• Mertz Philippe, Belot Alexandre, Cervera Ricard, Chuah Tyng Yu, Dagna Lorenzo, Damian Laura, Danda Debashish, d'Cruz David, Espinosa Gerard, Frances Camille, Jayne David, Ooi Kong Kok, Kucharz Eugene J., Lebovics Robert, Marie Isabelle, Moulis Guillaume, Peng Stanford, Sharma Aman, Suzuki Noboru, Tanaka Toshio, van Vollenhoven Ronald, Sibilia Jean, Gottenberg Jacques Eric, Chasset François, Arnaud Laurent Le Relapsing Polychondritis Damage Index (RPDAM): développement d'un score lésionnel au cours de la polychondrite atrophiante Revue du Rhumatisme (Edition Francaise) 2020;87 (2):122-127
• van Vollenhoven Ronald F., Hahn Bevra H., Tsokos George C., Lipsky Peter, Fei Kaiyin, Gordon Robert M., Gregan Irene, Lo Kim Hung, Chevrier Marc, Rose Shawn Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus Arthritis & rheumatology (Hoboken, N.J.) 2020;72 (5):761-768 [PubMed]
• Hanly John G., Urowitz Murray B., Gordon Caroline, Bae Sang-Cheol, Romero-Diaz Juanita, Sanchez-Guerrero Jorge, Bernatsky Sasha, Clarke Ann E., Wallace Daniel J., Isenberg David A., Rahman Anisur, Merrill Joan T., Fortin Paul R., Gladman Dafna D., Bruce Ian N., Petri Michelle, Ginzler Ellen M., Dooley Mary Anne, Ramsey-Goldman Rosalind, Manzi Susan, Jönsen Andreas, Alarcón Graciela S., van Vollenhoven Ronald F., Aranow Cynthia, MacKay Meggan, Ruiz-Irastorza Guillermo, Lim Sam, Inanc Murat, Kalunian Kenneth C., Jacobsen S. ren, Peschken Christine A., Kamen Diane L., Askanase Anca, Farewell Vernon Neuropsychiatric events in systemic lupus erythematosus: A longitudinal analysis of outcomes in an international inception cohort using a multistate model approach Annals of the rheumatic diseases 2020 [PubMed]
• Vedder D., Gerritsen M., Duvvuri B., van Vollenhoven R. F., Nurmohamed M. T., Lood C. Neutrophil activation identifies patients with active polyarticular gout Arthritis research & therapy 2020;22 (1):148 [PubMed]
• Hooijberg Femke, Boekel Laura, Vogelzang Erik H., Leeuw Maureen, Boers Maarten, van Vollenhoven Ronald, Lems Willem F., Nurmohamed Mike T., Wolbink Gertjan Patients with rheumatic diseases adhere to COVID-19 isolation measures more strictly than the general population The Lancet Rheumatology 2020;2 (10):e583-e585
• Hanly John G., Li Qiuju, Su Li, Urowitz Murray B., Gordon Caroline, Bae Sang-Cheol, Romero-Diaz Juanita, Sanchez-Guerrero Jorge, Bernatsky Sasha, Clarke Ann E., Wallace Daniel J., Isenberg David A., Rahman Anisur, Merrill Joan T., Fortin Paul R., Gladman Dafna D., Bruce Ian N., Petri Michelle, Ginzler Ellen M., Dooley M. A., Steinsson Kristjan, Ramsey-Goldman Rosalind, Zoma Asad A., Manzi Susan, Nived Ola, Jonsen Andreas, Khamashta Munther A., Alarcón Graciela S., Svenungsson Elisabet, van Vollenhoven Ronald F., Aranow Cynthia, Mackay Meggan, Ruiz-Irastorza Guillermo, Ramos-Casals Manuel, Lim S. Sam, Inanc Murat, Kalunian Kenneth C., Jacobsen Soren, Peschken Christine A., Kamen Diane L., Askanase Anca, Theriault Chris, Farewell Vernon Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study Arthritis & rheumatology (Hoboken, N.J.) 2020;72 (1):67-77 [PubMed]
• l'Ami Merel J., Krieckaert Charlotte L., Nurmohamed Michael T., van Vollenhoven Ronald F., Rispens Theo, Boers Maarten, Wolbink Gerrit Jan Response to: 'Tapering without relapse in rheumatoid arthritis patients with high TNF blocker concentrations: Data from the STRASS study' by Marotte et al Annals of the rheumatic diseases 2020;79 (7) [PubMed]
• Sepriano Alexandre, Kerschbaumer Andreas, Smolen Josef S., van der Heijde D. sirée, Dougados Maxime, van Vollenhoven Ronald, McInnes Iain B., Bijlsma Johannes W., Burmester Gerd R., de Wit Maarten, Falzon Louise, Landewé Robert Safety of synthetic and biological DMARDs: A systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis Annals of the rheumatic diseases 2020;79 (6):S760-S770 [PubMed]
• Cohen Stanley B., van Vollenhoven Ronald F., Winthrop Kevin L., Zerbini Cristiano A. F., Tanaka Yoshiya, Bessette Louis, Zhang Ying, Khan Nasser, Hendrickson Barbara, Enejosa Jeffrey V., Burmester Gerd R. Safety profile of upadacitinib in rheumatoid arthritis: Integrated analysis from the SELECT phase III clinical programme Annals of the rheumatic diseases 2020 [PubMed]
• van Vollenhoven Ronald String of successful trials in SLE: Have we cracked the code? Lupus science & medicine 2020;7 (1) [PubMed]
• Cesaroni Matteo, Seridi Loqmane, Loza Matthew J., Schreiter Jessica, Sweet Kristen, Franks Carol, Ma Keying, Orillion Ashley, Campbell Kim, M. Gordon Robert, Branigan Patrick, Lipsky Peter, van Vollenhoven Ronald, Hahn Bevra H., Tsokos George C., Chevrier Marc, Rose Shawn, Baribaud Frédéric, Jordan Jarrat Suppression of Serum Interferon-γ Levels as a Potential Measure of Response to Ustekinumab Treatment in Patients With Systemic Lupus Erythematosus Arthritis & rheumatology (Hoboken, N.J.) 2020 [PubMed]
• Ríos-Garcés Roberto, Espinosa Gerard, van Vollenhoven Ronald, Cervera Ricard Treat-to-target in systemic lupus erythematosus: Where are we? European journal of internal medicine 2020;74:29-34 [PubMed]
• Takeuchi Tsutomu, Rischmueller Maureen, Blanco Ricardo, Xavier Ricardo M., Ueki Yukitaka, Atsumi Tatsuya, Chen Su, Friedman Alan, Pangan Aileen L., Strand Vibeke, van Vollenhoven Ronald F. Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: a sub-analysis of the Phase 3 SELECT-EARLY study Modern rheumatology / the Japan Rheumatism Association 2020 [PubMed]

2019

• Ehlers Lisa, Askling Johan, Bijlsma Hans W. J., Cid Maria Cinta, Cutolo Maurizio, Dasgupta Bhaskar, Dejaco Christian, Dixon William G., Feltelius Nils, Finckh Axel, Gilbert Kate, Mackie Sarah Louise, Mahr Alfred, Matteson Eric L., Neill Lorna, Salvarani Carlo, Schmidt Wolfgang A., Strangfeld Anja, van Vollenhoven Ronald F., Buttgereit Frank 2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis Annals of the rheumatic diseases 2019;78 (9):1160-1166 [PubMed]
• Fanouriakis Antonis, Kostopoulou Myrto, Alunno Alessia, Aringer Martin, Bajema Ingeborg, Boletis John N., Cervera Ricard, Doria Andrea, Gordon Caroline, Govoni Marcello, Houssiau Frédéric, Jayne David, Kouloumas Marios, Kuhn Annegret, Larsen Janni L., Lerstrøm Kirsten, Moroni Gabriella, Mosca Marta, Schneider Matthias, Smolen Josef S., Svenungsson Elisabet, Tesar Vladimir, Tincani Angela, Troldborg Anne, van Vollenhoven Ronald, Wenzel J. rg, Bertsias George, Boumpas Dimitrios T. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus Annals of the rheumatic diseases 2019;78 (6):736-745 [PubMed]
• van Vollenhoven Ronald F. Assessing joint inflammation-a way forward for SLE trials? Rheumatology (Oxford, England) 2019;58 (8):1327-1328 [PubMed]
• Hambardzumyan K., Hermanrud C., Marits P., Vivar N., Ernestam S., Wallman J. K., van Vollenhoven R. F., Fogdell-Hahn A., Saevarsdottir S. Association of female sex and positive rheumatoid factor with low serum infliximab and anti-drug antibodies, related to treatment failure in early rheumatoid arthritis: results from the SWEFOT trial population Scandinavian journal of rheumatology 2019;48 (5):362-366 [PubMed]
• Parodis Ioannis, Emamikia Sharzad, Gomez Alvaro, Gunnarsson Iva, van Vollenhoven Ronald F., Chatzidionysiou Katerina Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies Expert opinion on biological therapy 2019;19 (2):157-168 [PubMed]
• Parodis Ioannis, Emamikia Sharzad, Gomez Alvaro, Gentline Cidem, Arkema Elizabeth V., Chatzidionysiou Katerina, van Vollenhoven Ronald F. Definitions of remission in systemic lupus erythematosus: a post-hoc analysis of two randomised clinical trials The Lancet Rheumatology 2019;1 (3):e163-e173
• Berkhout Lea C., l'Ami Merel J., Ruwaard Jill, Hart Margreet H., Ooijevaar-de Heer Pleuni, Bloem Karien, Nurmohamed Michael T., van Vollenhoven Ronald F., Boers Maarten, Alvarez Daniel F., Smith Catherine H., Wolbink Gerrit J., Rispens Theo Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay Science translational medicine 2019;11 (477) [PubMed]
• van Vollenhoven Ronald, Lee Eun Bong, Strengholt Sander, Mojcik Christopher, Valdez Hernan, Krishnaswami Sriram, Biswas Pinaki, Lazariciu Irina, Hazra Anasuya, Clark James D., Hodge Jennifer, Wang Lisy, Choy Ernest Evaluation of the Short-, Mid-, and Long-Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis Arthritis & rheumatology (Hoboken, N.J.) 2019;71 (5):685-695 [PubMed]
• Al-Soudi A, Doorenspleet M E, Esveldt R E, Burgemeister L T, Hak A E, van den Born B J H, Tas S W, van Vollenhoven R F, Klarenbeek P L, de Vries N IgG4:IgG RNA ratio differentiates active disease from remission in granulomatosis with polyangiitis: a new disease activity marker? A cross-sectional and longitudinal study Arthritis research & therapy 2019;21 (1):43 [PubMed]
• Iaccarino Luca, Talarico Rosaria, Scirè Carlo Alberto, Amoura Zahir, Burmester Gerd, Doria Andrea, Faiz Karim, Frank Charissa, Hachulla Eric, Hie Miguel, Launay David, Montecucco Carlomaurizio, Monti Sara, Mouthon Luc, Tincani Angela, Toniati Paola, van Hagen Pieter Martin, van Vollenhoven Ronald F., Bombardieri Stefano, Mueller-Ladner Ulf, Schneider Matthias, Smith Vanessa, Cutolo Maurizio, Mosca Marta, Alexander Tobias IgG4-related diseases: State of the art on clinical practice guidelines RMD open 2019;4 (Suppl 1):e000787 [PubMed]
• Levitsky Adrian, Kisten Yogan, Lind Sara, Nordström Patric, Hultholm Helene, Lyander Jessica, Hammelin Viveka, Gentline Cidem, Giannakou Ioanna, Faustini Francesca, Skillgate Eva, van Vollenhoven Ronald, Sundberg Tobias Joint Mobilization of the Hands of Patients With Rheumatoid Arthritis: Results From an Assessor-Blinded, Randomized Crossover Trial Journal of manipulative and physiological therapeutics 2019;42 (1):34-46 [PubMed]
• van Vollenhoven Ronald F., Nurmohamed Michael Methotrexate for prevention of cardiovascular events New England journal of medicine 2019;380 (23):2276-2277 [PubMed]
• Wirestam Lina, Enocsson Helena, Skogh Thomas, Padyukov Leonid, Jönsen Andreas, Urowitz Murray B., Gladman Dafna D., Romero-DIaz Juanita, Bae Sang-Cheol, Fortin Paul R., Sanchez-Guerrero Jorge, Clarke Ann E., Bernatsky Sasha, Gordon Caroline, Hanly John G., Wallace Daniel, Isenberg David A., Rahman Anisur, Merrill Joan, Ginzler Ellen, Alarcón Graciela S., Chatham W. Winn, Petri Michelle, Khamashta Munther, Aranow Cynthia, MacKay Meggan, Dooley Mary Anne, Manzi Susan, Ramsey-Goldman Rosalind, Nived Ola, Steinsson Kristjan, Zoma Asad, Ruiz-Irastorza Guillermo, Lim Sam, Kalunian Ken, Inanc Murat, van Vollenhoven Ronald, Ramos-Casals Manuel, Kamen Diane L., Jacobsen S. ren, Peschken Christine, Askanase Anca, Stoll Thomas, Bruce Ian N., Wetterö Jonas, Sjöwall Christopher Osteopontin and disease activity in patients with recent-onset systemic Lupus Erythematosus: Results from the SLICC Inception Cohort Journal of rheumatology 2019;46 (5):492-500 [PubMed]
• Legge Alexandra, Kirkland Susan, Rockwood Kenneth, Andreou Pantelis, Bae Sang-Cheol, Gordon Caroline, Romero-Diaz Juanita, Sanchez-Guerrero Jorge, Wallace Daniel J., Bernatsky Sasha, Clarke Ann E., Merrill Joan T., Ginzler Ellen M., Fortin Paul R., Gladman Dafna D., Urowitz Murray B., Bruce Ian N., Isenberg David A., Rahman Anisur, Alarcón Graciela S., Petri Michelle, Khamashta Munther A., Dooley M. A., Ramsey-Goldman Rosalind, Manzi Susan, Zoma Asad A., Aranow Cynthia, Mackay Meggan, Ruiz-Irastorza Guillermo, Lim S. Sam, Inanc Murat, van Vollenhoven Ronald F., Jonsen Andreas, Nived Ola, Ramos-Casals Manuel, Kamen Diane L., Kalunian Kenneth C., Jacobsen Soren, Peschken Christine A., Askanase Anca, Hanly John G. Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index Arthritis & rheumatology (Hoboken, N.J.) 2019 [PubMed]
• Hambardzumyan Karen, Bolce Rebecca J., Wallman Johan K., van Vollenhoven Ronald F., Saevarsdottir Saedis Serum biomarkers for prediction of response to methotrexate monotherapy in early rheumatoid arthritis: Results from the SWEFOT trial Journal of rheumatology 2019;46 (6):555-563 [PubMed]
• l’ Ami M. J., Ruwaard J., Krieckaert C. L. M., Nurmohamed M. T., van Vollenhoven R. F., Rispens T., Wolbink G. J. Serum drug concentrations to optimize switching from adalimumab to etanercept in rheumatoid arthritis Scandinavian journal of rheumatology 2019;48 (4):266-270 [PubMed]
• Chatzidionysiou K., Lukina G., Gabay C., Hetland M. L., Hauge E. M., Pavelka K., Nordström D., Canhão H., Tomsic M., Rotar Z., Lie E., Kvien T. K., van Vollenhoven R. F., Saevarsdottir S. Smoking and response to rituximab in rheumatoid arthritis: results from an international European collaboration Scandinavian journal of rheumatology 2019;48 (1):17-23 [PubMed]
• Enocsson Helena, Wirestam Lina, Dahle Charlotte, Padyukov Leonid, Jönsen Andreas, Urowitz Murray B., Gladman Dafna D., Romero-Diaz Juanita, Bae Sang-Cheol, Fortin Paul R., Sanchez-Guerrero Jorge, Clarke Ann E., Bernatsky Sasha, Gordon Caroline, Hanly John G., Wallace Daniel J., Isenberg David A., Rahman Anisur, Merrill Joan T., Ginzler Ellen, Alarcón Graciela S., Chatham W. Winn, Petri Michelle, Khamashta Munther, Aranow Cynthia, Mackay Meggan, Dooley Mary Anne, Manzi Susan, Ramsey-Goldman Rosalind, Nived Ola, Steinsson Kristjan, Zoma Asad A., Ruiz-Irastorza Guillermo, Lim S. Sam, Kalunian Kenneth C., Inanc Murat, van Vollenhoven Ronald F., Ramos-Casals Manuel, Kamen Diane L., Jacobsen S. ren, Peschken Christine A., Askanase Anca, Stoll Thomas, Bruce Ian N., Wetterö Jonas, Sjöwall Christopher Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus Journal of autoimmunity 2019 [PubMed]
• Mertz Philippe, Belot Alexandre, Cervera Ricard, Chuah Tyng Yu, Dagna Lorenzo, Damian Laura, Danda Debashish, D'cruz David, Espinosa Gerard, Frances Camille, Jayne David, Ooi Kong Kok, Kucharz Eugene J., Lebovics Robert, Marie Isabelle, Moulis Guillaume, Peng Stanford, Sharma Aman, Suzuki Noboru, Tanaka Toshio, van Vollenhoven Ronald, Sibilia Jean, Gottenberg Jacques Eric, Chasset François, Arnaud Laurent The relapsing polychondritis damage index (RPDAM): Development of a disease-specific damage score for relapsing polychondritis Joint, bone, spine 2019;86 (3):363-368 [PubMed]
• den Broeder Nathan, Bouman Chantal A. M., Kievit Wietske, van Herwaarden Noortje, van den Hoogen Frank H. J., van Vollenhoven Ronald F., Bijlsma Hans W. J., van der Maas Aatke, den Broeder Alfons A. Three-year cost-effectiveness analysis of the DRESS study: Protocolised tapering is key Annals of the rheumatic diseases 2019;78 (1):141-142 [PubMed]
• van Vollenhoven Ronald Treat-to-target in rheumatoid arthritis — are we there yet? Nature reviews. Rheumatology 2019;15 (3):180-186 [PubMed]
• Antunes Margarida, Scirè Carlo Alberto, Talarico Rosaria, Alexander Tobias, Avcin Tadej, Belocchi Chiara, Doria Andrea, Franceschini Franco, Galetti Ilaria, Govoni Marcello, Hachulla Eric, Launay David, Lepri Gemma, Macieira Carla, Matucci-Cerinic Marco, Montecucco Carlo Maurizio, Moraes-Fontes Maria Francisca, Mouthon Luc, Paolino Sabrina, Ramoni Veronique, Tani Chiara, Tas Sander W., Tincani Angela, van Vollenhoven Ronald, Zen Margherita, Fonseca Joao, Bombardieri Stefano, Fonseca João Eurico, Schneider Matthias, Smith Vanessa, Cutolo Maurizio, Mosca Marta, Beretta Lorenzo Undifferentiated connective tissue disease: State of the art on clinical practice guidelines RMD open 2019;4 (Suppl 1):e000786 [PubMed]
• Mendel Arielle, Bernatsky Sasha, Pineau Christian A., St-Pierre Yvan, Hanly John G., Urowitz Murray B., Clarke Ann E., Romero-Diaz Juanita, Gordon Caroline, Bae Sang-Cheol, Wallace Daniel J., Merrill Joan T., Buyon Jill, Isenberg David A., Rahman Anisur, Ginzler Ellen M., Petri Michelle, Dooley Mary Anne, Fortin Paul, Gladman Dafna D., Steinsson Kristján, Ramsey-Goldman Rosalind, Khamashta Munther A., Aranow Cynthia, MacKay Meggan, Alarcón Graciela, Manzi Susan, Nived Ola, Jönsen Andreas, Zoma Asad A., van Vollenhoven Ronald F., Ramos-Casals Manuel, Ruiz-Irastorza Giuillermo, Lim Sam, Kalunian Kenneth C., Inanc Murat, Kamen Diane L., Peschken Christine A., Jacobsen S. ren, Askanase Anca, Sanchez-Guerrero Jorge, Bruce Ian N., Costedoat-Chalumeau Nathalie, Vinet Evelyne Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen Rheumatology (Oxford, England) 2019;58 (7):1259-1267 [PubMed]

2018

• Arnaud Laurent, van Vollenhoven Ronald Advanced Handboek of Systemic Lupus Erythematosus Springer International Publishing Switzerland; 2018. 167p. ISBN 9783319430348
• Kivitz Alan J., Cohen Stanley, Keystone Edward, van Vollenhoven Ronald F., Haraoui Boulos, Kaine Jeffrey, Fan Haiyun, Connell Carol A., Bananis Eustratios, Takiya Liza, Fleischmann Roy A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population Seminars in arthritis and rheumatism 2018;48 (3):406-415 [PubMed]
• Costedoat-Chalumeau Nathalie, Houssiau Frédéric, Izmirly Peter, Guern V. ronique Le, Navarra Sandra, Jolly Meenakshi, Ruiz-Irastorza Guillermo, Baron Gabriel, Hachulla Eric, Agmon-Levin Nancy, Shoenfeld Yehuda, Dall'Ara Francesca, Buyon Jill, Deligny Christophe, Cervera Ricard, Lazaro Estibaliz, Bezanahary Holy, Leroux Gaëlle, Morel Nathalie, Viallard Jean-François, Pineau Christian, Galicier Lionel, van Vollenhoven Ronald, Tincani Angela, Nguyen Hanh, Gondran Guillaume, Zahr Noel, Pouchot Jacques, Piette Jean-Charles, Petri Michelle, Isenberg David A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires Clinical pharmacology and therapeutics 2018;103 (6):1074-1082 [PubMed]
• Hanly John G., Li Qiuju, Su Li, Urowitz Murray B., Gordon Caroline, Bae Sang-Cheol, Romero-Diaz Juanita, Sanchez-Guerrero Jorge, Bernatsky Sasha, Clarke Ann E., Wallace Daniel J., Isenberg David A., Rahman Anisur, Merrill Joan T., Fortin Paul, Gladman Dafna D., Bruce Ian N., Petri Michelle, Ginzler Ellen M., Dooley M. A., Steinsson Kristjan, Ramsey-Goldman Rosalind, Zoma Asad A., Manzi Susan, Nived Ola, Jonsen Andreas, Khamashta Munther A., Alarcón Graciela S., Chatham Winn, van Vollenhoven Ronald F., Aranow Cynthia, Mackay Meggan, Ruiz-Irastorza Guillermo, Ramos-Casals Manuel, Lim S. Sam, Inanc Murat, Kalunian Kenneth C., Jacobsen Soren, Peschken Christine A., Kamen Diane L., Askanase Anca, Theriault Chris, Farewell Vernon Cerebrovascular Events in Systemic Lupus Erythematosus Arthritis care & research 2018;70 (10):1478-1487 [PubMed]
• van Vollenhoven Ronald F., Stohl William, Furie Richard A., Fox Norma Lynn, Groark James G., Bass Damon, Kurtinecz Milena, Pobiner Bonnie F., Eastman William J., Gonzalezarivera Tania, Gordon David Clinical response beyond the systemic lupus erythematosus responder index: Post-hoc analysis of the BLISS-SC study Lupus science & medicine 2018;5 (1) [PubMed]
• van der Heijde D. sirée, Daikh David I., Betteridge Neil, Burmester Gerd R., Hassett Afton L., Matteson Eric L., van Vollenhoven Ronald, Lakhanpal Sharad Common language description of the term rheumatic and musculoskeletal diseases (RMDs) for use in communication with the lay public, healthcare providers and other stakeholders endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) Annals of the rheumatic diseases 2018;77 (6):829-832 [PubMed]
• van der Heijde D. sirée, Daikh David I., Betteridge Neil, Burmester Gerd R., Hassett Afton L., Matteson Eric L., van Vollenhoven Ronald, Lakhanpal Sharad Common Language Description of the Term Rheumatic and Musculoskeletal Diseases (RMDs) for Use in Communication With the Lay Public, Healthcare Providers, and Other Stakeholders Endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) Arthritis & rheumatology (Hoboken, N.J.) 2018;70 (6):826-831 [PubMed]
• Lourdudoss Cecilia, Di Giuseppe Daniela, Wolk Alicja, Westerlind Helga, Klareskog Lars, Alfredsson Lars, van Vollenhoven Ronald F., Lampa Jon Dietary Intake of Polyunsaturated Fatty Acids and Pain in Spite of Inflammatory Control Among Methotrexate-Treated Early Rheumatoid Arthritis Patients Arthritis care & research 2018;70 (2):205-212 [PubMed]
• Barber Megan R. W., Hanly John G., Su Li, Urowitz Murray B., Pierre Yvan St, Romero-Diaz Juanita, Gordon Caroline, Bae Sang-Cheol, Bernatsky Sasha, Wallace Daniel J., Isenberg David A., Rahman Anisur, Ginzler Ellen M., Petri Michelle, Bruce Ian N., Fortin Paul R., Gladman Dafna D., Sanchez-Guerrero Jorge, Ramsey-Goldman Rosalind, Khamashta Munther A., Aranow Cynthia, Mackay Meggan, Alarcón Graciela S., Manzi Susan, Nived Ola, Jönsen Andreas, Zoma Asad A., van Vollenhoven Ronald F., Ramos-Casals Manuel, Ruiz-Irastorza Guillermo, Sam Lim S., Kalunian Kenneth C., Inanc Murat, Kamen Diane L., Peschken Christine A., Jacobsen Soren, Askanase Anca, Theriault Chris, Farewell Vernon, Clarke Ann E. Economic evaluation of lupus nephritis in the Systemic Lupus International Collaborating Clinics inception cohort using a multistate model approach Arthritis care & research 2018;70 (9):1294-1302 [PubMed]
• Doria A., Stohl W., Schwarting A., Okada M., Scheinberg M., van Vollenhoven R., Hammer A. E., Groark J., Bass D., Fox N. L., Roth D., Gordon D. Efficacy and Safety of Subcutaneous Belimumab in Anti–Double-Stranded DNA–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus Arthritis & rheumatology (Hoboken, N.J.) 2018;70 (8):1256-1264 [PubMed]
• van Vollenhoven Ronald F., Keystone Edward Clark, Strand Vibeke, Pacheco-Tena Cesar, Vencovský Jiří, Behrens Frank, Racewicz Arthur, Zipp Daniela, Rharbaoui Faiza, Wolter Ralf, Knierim Luise, Schmeidl Rainer, Zhou Xuefei, Aigner Silke, Dälken Benjamin, Wartenberg-Demand Andrea, Aelion Jacob, Arreola Jorge Aguilar, Arias Maria Araujo, Back Johan, Baranauskaite Asta, Bennett Ralph, Bookman Arthur, Brzezicki Jan, Butrimiene Irena, Churchill Melvin, Djacenko Svetlana, Dokoupilova Eva, Drescher Edit, Dudek Anna, Edwards William, Eliseeva Larisa, Ershova Olga, Fortin Isabelle, Galatikova Dagmar, de la Torre Ignacio Garcia, Garmish Olena, Gasanov Yuriy, Gnylorybov Andriy, Goldberg Marc, Golovchenko Oleksandr, Gordeev Ivan, Hiepe Falk, Sil Gabriela Huerta, Husarova Viola, Iaremenko Oleg, Jeka Slawomir, Kamburova Daniela, Kavanaugh Arthur, Keszthelyi Peter Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial Annals of the rheumatic diseases 2018;77 (4):495-499 [PubMed]
• van Vollenhoven Ronald F., Hahn Bevra H., Tsokos George C., Wagner Carrie L., Lipsky Peter, Touma Zahi, Werth Victoria P., Gordon Robert M., Zhou Bei, Hsu Benjamin, Chevrier Marc, Triebel Manon, Jordan Jarrat L., Rose Shawn Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study Lancet 2018;392 (10155):1330-1339 [PubMed]
• van de Sande Marleen G. H., van Vollenhoven Ronald F. Evolution of clinical trials for rheumatoid arthritis and spondyloarthritis Current opinion in rheumatology 2018;30 (4):340-346 [PubMed]
• Rusman T., van Vollenhoven R. F., van der Horst-Bruinsma I. E. Gender Differences in Axial Spondyloarthritis: Women Are Not So Lucky Current rheumatology reports 2018;20 (6) [PubMed]
• Taylor John C., Bongartz Tim, Massey Jonathan, Mifsud Borbala, Spiliopoulou Athina, Scott Ian C., Wang Jianmei, Morgan Michael, Plant Darren, Colombo Marco, Orchard Peter, Twigg Sarah, McInnes Iain B., Porter Duncan, Freeston Jane E., Nam Jackie L., Cordell Heather J., Isaacs John D., Strathdee Jenna L., Arnett Donna, de Hair Maria J. H., Tak Paul P., Aslibekyan Stella, van Vollenhoven Ronald F., Padyukov Leonid, Bridges S. Louis, Pitzalis Costantino, Cope Andrew P., Verstappen Suzanne M. M., Emery Paul, Barnes Michael R., Agakov Felix, McKeigue Paul, Mushiroda Taisei, Kubo Michiaki, Weinshilboum Richard, Barton Anne, Morgan Ann W., Barrett Jennifer H. Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients pharmacogenomics journal 2018;18 (4):528-538 [PubMed]
• van Vollenhoven R. F. Genotypes, phenotypes and treatment with immunomodulators in the rheumatic diseases Journal of internal medicine 2018;284 (3):228-239 [PubMed]
• Little Jayne, Parker Ben, Lunt Mark, Hanly John G., Urowitz Murray B., Clarke Ann E., Romero-Diaz Juanita, Gordon Caroline, Bae Sang-Cheol, Bernatsky Sasha, Wallace Daniel J., Merrill Joan T., Buyon Jill, Isenberg David A., Rahman Anisur, Ginzler Ellen M., Petri Michelle, Dooley Mary Anne, Fortin Paul, Gladman Dafna D., Steinsson Kristjan, Ramsey-Goldman Rosalind, Khamashta Munther A., Aranow Cynthia, Mackay Meggan, Alarcón Graciela S., Manzi Susan, Nived Ola, Jönsen Andreas, Zoma Asad A., van Vollenhoven Ronald F., Ramos-Casals Manuel, Ruiz-Irastorza Guillermo, Sam Lim Sung, Kalunian Kenneth C., Inanc Murat, Kamen Diane L., Peschken Christine A., Jacobsen Soren, Askanase Anca, Sanchez-Guerrero Jorge, Bruce Ian N. Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort Rheumatology (Oxford, England) 2018;57 (4):677-687 [PubMed]
• Lourdudoss Cecilia, Arnaud Laurent, Wolk Alicja, van Vollenhoven Ronald F., di Giuseppe Daniela Long-Term Dietary Changes after Diagnosis of Rheumatoid Arthritis in Swedish Women: Data from a Population-Based Cohort International journal of rheumatology 2018;2018 [PubMed]
• Benjamin Chaigne, Carlo Alberto Scirè, Rosaria Talarico, Tobias Alexander, Zahir Amoura, Tadej Avcin, Lorenzo Beretta, Andrea Doria, Aurelien Guffroy, Vera Guimarães, Éric Hachulla, Thomas Krieg, David Launay, Gemma Lepri, Pia Moinzadeh, Ulf M. ller-Ladner, Simona Rednic, Ana Rodrigues, Tas Sander W., van Vollenhoven R. F., Ana Vieira, Stefano Bombardieri, Eurico Fonseca João, Ilaria Galetti, Matthias Schneider, Vanessa Smith, Maurizio Cutolo, Marta Mosca, Rebecca Fischer-Betz Mixed connective tissue disease: State of the art on clinical practice guidelines RMD open 2018;4 [PubMed]
• Barturen Guillermo, Beretta Lorenzo, Cervera Ricard, van Vollenhoven Ronald, Alarcón-Riquelme Marta E. Moving towards a molecular taxonomy of autoimmune rheumatic diseases Nature reviews. Rheumatology 2018;14 (2):75-93 [PubMed]
• van Vollenhoven R. F., l'Ami M., Wolbink G. Personalised medicine in de reumatologie Tijdschrift voor psychiatrie 2018;60 (3):146-150 [PubMed]
• Smolen Josef S., van Vollenhoven Ronald F., Florentinus Stefan, Chen Su, Suboticki Jessica L., Kavanaugh Arthur Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate Annals of the rheumatic diseases 2018;77 (11):1566-1572 [PubMed]
• Giannakou Ioanna, Chatzidionysiou Katerina, Magder Laurence S., Györi Noemi, van Vollenhoven Ronald, Petri Michelle A. Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: Results from the Hopkins Lupus Cohort Lupus science & medicine 2018;5 (1) [PubMed]
• Emamikia S., Gentline C., Chatzidionysiou K., Arnaud L., van Vollenhoven R. Relationship between glucocorticoid dose and adverse events in systemic lupus erythematosus: data from a randomized clinical trial Scandinavian journal of rheumatology 2018;47 (2):131-140 [PubMed]
• l'Ami Merel J., Krieckaert Charlotte L. M., Nurmohamed Michael T., van Vollenhoven Ronald F., Rispens Theo, Boers Maarten, Wolbink Gerrit Jan Response to: Comment on l'Ami et al titled 'Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial' by den Broeder et al Annals of the rheumatic diseases 2018;77 (10) [PubMed]
• Lesuis Nienke, van Vollenhoven Ronald F., Akkermans Reinier P., Verhoef Lise M., Hulscher Marlies E., den Broeder Alfons A. Rheumatologists' guideline adherence in rheumatoid arthritis: a randomised controlled study on electronic decision support, education and feedback Clinical and experimental rheumatology 2018;36 (1):21-28 [PubMed]
• Parodis I., Söder F., Faustini F., Kasza Z., Samuelsson I., Zickert A., Svenungsson E., van Vollenhoven R. F., Malmström V., Wermeling F., Gunnarsson I. Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus – distinct roles of BAFF and APRIL Lupus 2018;27 (9):1470-1478 [PubMed]
• Isenberg D., Sturgess J., Allen E., Aranow C., Askanase A., Sang-Cheol B., Bernatsky S., Bruce I., Buyon J., Cervera R., Clarke A., Dooley Mary Anne, Fortin P., Ginzler E., Gladman D., Hanly J., Inanc M., Jacobsen S., Kamen D., Khamashta M., Lim S., Manzi S., Nived O., Peschken C., Petri M., Kalunian K., Rahman A., Ramsey-Goldman R., Romero-Diaz J., Ruiz-Irastorza G., Sanchez-Guerrero J., Steinsson K., Sturfelt G., Urowitz M., van Vollenhoven R., Wallace D. J., Zoma A., Merrill J., Gordon C. Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients Arthritis care & research 2018;70 (1):98-103 [PubMed]
• l'Ami Merel J., Krieckaert Charlotte L. M., Nurmohamed Michael T., van Vollenhoven Ronald F., Rispens Theo, Boers Maarten, Wolbink Gerrit Jan Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial Annals of the rheumatic diseases 2018;77 (4):484-487 [PubMed]
• Tamirou Farah, Arnaud Laurent, Talarico Rosaria, Scirè Carlo Alberto, Alexander Tobias, Amoura Zahir, Avcin Tadej, Bortoluzzi Alessandra, Cervera Ricard, Conti Fabrizio, Cornet Alain, Devilliers Hervé, Doria Andrea, Frassi Micol, Fredi Micaela, Govoni Marcello, Houssiau Frederic, Lladò Ana, Macieira Carla, Martin Thierry, Massaro Laura, Moraes-Fontes Maria Francisca, Pamfil Cristina, Paolino Sabrina, Tani Chiara, Tas Sander W., Tektonidou Maria, Tincani Angela, van Vollenhoven Ronald F., Bombardieri Stefano, Burmester Gerd, Eurico Fonseca João, Galetti Ilaria, Hachulla Eric, Mueller-Ladner Ulf, Schneider Matthias, Smith Vanessa, Cutolo Maurizio, Mosca Marta, Costedoat-Chalumeau Nathalie Systemic lupus erythematosus: State of the art on clinical practice guidelines RMD open 2018;4 (2)
• Smith Vanessa, Scirè Carlo Alberto, Talarico Rosaria, Airo Paolo, Alexander Tobias, Allanore Yannick, Bruni Cosimo, Codullo Veronica, Dalm Virgil, de Vries-Bouwstra Jeska, Della Rossa Alessandra, Distler Oliver, Galetti Ilaria, Launay David, Lepri Gemma, Mathian Alexis, Mouthon Luc, Ruaro Barbara, Sulli Alberto, Tincani Angela, Vandecasteele Els, Vanhaecke Amber, Vanthuyne Marie, van den Hoogen Frank, van Vollenhoven Ronald, Voskuyl Alexandre E., Zanatta Elisabetta, Bombardieri Stefano, Burmester Gerd, Eurico Fonseca João, Frank Charissa, Hachulla Eric, Houssiau Frederic, Mueller-Ladner Ulf, Schneider Matthias, van Laar Jacob M., Vieira Ana, Cutolo Maurizio, Mosca Marta, Matucci-Cerinic Marco Systemic sclerosis: State of the art on clinical practice guidelines RMD open 2018;4 [PubMed]
• Kavanaugh Arthur, van Vollenhoven Ronald F., Fleischmann Roy, Emery Paul, Sainsbury Iain, Florentinus Stefan, Chen Su, Guérette Benoît, Kupper Hartmut, Smolen Josef S. Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis Annals of the rheumatic diseases 2018;77 (2):289-292 [PubMed]
• Winthrop Kevin L., Strand Vibeke, van der Heijde Désirée, Mease Philip, Crow Mary, Weinblatt Michael, Bathon Joan, Burmester Gerd R., Dougados Maxime, Kay Johnathan, Mariette Xavier, van Vollenhoven Ronald, Sieper Joachim, Melchers Fritz, Breedfeld Ferdinand C., Kalden Joachim, Smolen Josef S., Furst Daniel E. The unmet need in rheumatology: Reports from the targeted therapies meeting 2017 Clinical immunology (Orlando, Fla.) 2018;186:87-93 [PubMed]
• de Vries Mirjam K., Arkema Elizabeth V., Jonsson Jerker, Bruchfeld Judith, Jacobsson Lennart T. H., Askling Johan, Klareskog Lars, van Vollenhoven Ronald, Feltelius Nils, Baecklund Eva, Kastbom Alf, Rantapää-Dahlqvist Solbritt, Forsblad-d'Elia Helena, Jacobsson Lennart, Turesson Carl, Lindqvist Elisabeth, Ernestam Sofia Tuberculosis Risk in Ankylosing Spondylitis, Other Spondyloarthritis, and Psoriatic Arthritis in Sweden: A Population-Based Cohort Study Arthritis care and research 2018;70 (10):1563-1567 [PubMed]

2017

• Combe Bernard, Landewe Robert, Daien Claire I., Hua Charlotte, Aletaha Daniel, Álvaro-Gracia Jose María, Bakkers Margôt, Brodin Nina, Burmester Gerd R., Codreanu Catalin, Conway Richard, Dougados Maxime, Emery Paul, Ferraccioli Gianfranco, Fonseca Joao, Raza Karim, Silva-Fernández Lucía, Smolen Josef S., Skingle Diana, Szekanecz Zoltan, Kvien Tore K., van der Helm-van Mil Annette, van Vollenhoven Ronald 2016 update of the EULAR recommendations for the management of early arthritis Annals of the rheumatic diseases 2017;76 (6):948-959 [PubMed]
• Keystone Edward C., Breedveld Ferdinand C., van der Heijde Désirée, van Vollenhoven Ronald F., Emery Paul, Smolen Josef S., Sainsbury Iain, Florentinus Stefan, Kupper Hartmut, Chen Kun, Kavanaugh Arthur Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone RMD open 2017;3 (2):e000445 [PubMed]
• Hambardzumyan Karen, Saevarsdottir Saedis, Forslind Kristina, Petersson Ingemar F., Wallman Johan K., Ernestam Sofia, Bolce Rebecca J., van Vollenhoven Ronald F. A Multi-Biomarker Disease Activity Score and the Choice of Second-Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure Arthritis & rheumatology (Hoboken, N.J.) 2017;69 (5):953-963 [PubMed]
• Weinblatt Michael E., Bingham Clifton O., Burmester Gerd-Rüdiger, Bykerk Vivian P., Furst Daniel E., Mariette Xavier, van der Heijde Désirée, van Vollenhoven Ronald, VanLunen Brenda, Ecoffet Cécile, Cioffi Christopher, Emery Paul A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis Arthritis & rheumatology (Hoboken, N.J.) 2017;69 (10):1937-1948 [PubMed]
• Hellgren Karin, Dreyer Lene, Arkema Elizabeth V., Glintborg Bente, Jacobsson Lennart T. H., Kristensen Lars-Erik, Feltelius Nils, Hetland Merete Lund, Askling Johan, Baecklund Eva, Kastbom Alf, Turesson Carl, Lindqvist Elisabeth, Klareskog Lars, d'Elia Helena Forsblad, Rantapää-Dahlqvist Solbritt, van Vollenhoven Ronald Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers Annals of the rheumatic diseases 2017;76 (1):105-111 [PubMed]
• Emery P., Bingham C. O., Burmester G. R., Bykerk V. P., Furst D. E., Mariette X., van der Heijde D., van Vollenhoven R., Arendt C., Mountian I., Purcaru O., Tatla D., VanLunen B., Weinblatt M. E. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study Annals of the rheumatic diseases 2017;76 (1):96-104 [PubMed]
• Lesuis N., den Broeder A. A., van Vollenhoven R. F., Vriezekolk J. E., Hulscher Mejl Choosing wisely in daily practice: a mixed methods study on determinants of antinuclear antibody testing by rheumatologists Scandinavian journal of rheumatology 2017;46 (3):241-246 [PubMed]
• Györi Noémi, Giannakou Ioanna, Chatzidionysiou Katerina, Magder Laurence, van Vollenhoven Ronald F., Petri Michelle Disease activity patterns over time in patients with SLE: analysis of the Hopkins Lupus Cohort Lupus science & medicine 2017;4 (1):e000192 [PubMed]
• Hifinger M., Hiligsmann M., Ramiro S., Watson V., Severens J. L., Fautrel B., Uhlig T., van Vollenhoven R., Jacques P., Detert J., Canas da Silva J., Scirè C. A., Berghea F., Carmona L., Péntek M., Keat A., Boonen A. Economic considerations and patients' preferences affect treatment selection for patients with rheumatoid arthritis: a discrete choice experiment among European rheumatologists Annals of the rheumatic diseases 2017;76 (1):126-132 [PubMed]
• van Vollenhoven Ronald F. EDITORIAL Who Gets Lupus? Clues to a Tantalizing Syndrome Arthritis & rheumatology (Hoboken, N.J.) 2017;69 (3):483-486 [PubMed]
• Moots Robert J., Sebba Anthony, Rigby William, Ostor Andrew, Porter-Brown Benjamin, Donaldson Francis, Dimonaco Sophie, Rubbert-Roth Andrea, van Vollenhoven Ronald, Genovese Mark C. Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials Rheumatology (Oxford, England) 2017;56 (4):541-549 [PubMed]
• Nam Jackie L., Takase-Minegishi Kaoru, Ramiro Sofia, Chatzidionysiou Katerina, Smolen Josef S., van der Heijde Désirée, Bijlsma Johannes W., Burmester Gerd R., Dougados Maxime, Scholte-Voshaar Marieke, van Vollenhoven Ronald, Landewé Robert Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis Annals of the rheumatic diseases 2017;76 (6):1113-1136 [PubMed]
• Chatzidionysiou Katerina, Emamikia Sharzad, Nam Jackie, Ramiro Sofia, Smolen Josef, van der Heijde Désirée, Dougados Maxime, Bijlsma Johannes, Burmester Gerd, Scholte Marieke, van Vollenhoven Ronald, Landewé Robert Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis Annals of the rheumatic diseases 2017;76 (6):1102-1107 [PubMed]
• Platten Michael, Kisten Yogan, Kälvesten Johan, Arnaud Laurent, Forslind Kristina, van Vollenhoven Ronald Fully automated joint space width measurement and digital X-ray radiogrammetry in early RA RMD open 2017;3 (1):e000369 [PubMed]
• Glinatsi Daniel, Heiberg Marte S., Rudin Anna, Nordström Dan, Haavardsholm Espen A., Gudbjornsson Bjorn, Østergaard Mikkel, Uhlig Till, Grondal Gerdur, Hørslev-Petersen Kim, van Vollenhoven Ronald, Hetland Merete L. Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: study protocol for a multicenter, randomized, open-label, blinded-assessor, phase 4 study Trials 2017;18 (1):161 [PubMed]
• Lesuis N., Verhoef L. M., Nieboer L. M., Bruyn G. A., Baudoin P., van Vollenhoven R. F., Hulscher Mejl, van den Hoogen Fhj, den Broeder A. A. Implementation of protocolized tight control and biological dose optimization in daily clinical practice: results of a pilot study Scandinavian journal of rheumatology 2017;46 (2):152-155 [PubMed]
• Ramos-Remus Cesar, Ramirez-Gomez Andrea, Brambila-Barba Victor, Barajas-Ochoa Aldo, Castillo-Ortiz Jose D., Adebajo Adewale O., Espinoza Luis R., Aceves-Avila Francisco J., Sánchez-González Jorge M., Boudersa Nadia, Slimani Samy, Ladjouze-Rezig Aicha, Diaz Mónica P., Kirmayr Karin I., Asnal Cecilia A., Catoggio Luis J., Citera Gustavo, Casado Gustavo C., Alvarez Analia P., Pisoni Cecilia N., Benavente Emilio, Lopez-Cabanillas Adriana, Baez Roberto M., Pons-Estel Bernardo A., Sacnún Mónica P., Cavallasca Javier A., Paniego Raúl H., Proudman Susanna M., Thomas Ranjeny, Major Gabor, Mathers David M., Schrieber Leslie, Haq Syed A., Islam Nazrul, Dessein Patrick H., von Muhlen Carlos A., Bianchi Washington A., da R Castelar-Pinheiro Geraldo, Feldman-Pollak Daniel, Cossermelli Waldenise, Bonfiglioli Karina R., Giorgi Rina D., Zabsonre-Tiendrebeogo Wendlassida J., Russell Anthony S., Olaru Lilia, Karsh Jacob, Fuentealba Carlos, Aguilera Sergio, de Vries Niek, van Vollenhoven Ronald F. Latitude gradient influences the age of onset of rheumatoid arthritis: a worldwide survey Clinical rheumatology 2017;36 (3):485-497 [PubMed]
• Fleischmann Roy, van Vollenhoven Ronald F., Vencovský Jiri, Alten Rieke, Davies Owen, Mountian Irina, de Longueville Marc, Carter David, Choy Ernest Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients Rheumatology and therapy 2017;4 (1):57-69 [PubMed]
• Bouman Chantal Am, van Herwaarden Noortje, van den Hoogen Frank Hj, Fransen Jaap, van Vollenhoven Ronald F., Bijlsma Johannes Wj, Maas Aatke van der, den Broeder Alfons A. Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study - a randomised controlled pragmatic non-inferiority strategy trial Annals of the rheumatic diseases 2017;76 (10):1716-1722 [PubMed]
• Ferreira Isabel, Croca Sara, Raimondo Maria Gabriella, Matharu Manjit, Miller Sarah, Giles Ian, Isenberg David, Ioannou Yiannis, Hanly John G., Urowitz Murray B., Anderson Nicole, Aranow Cynthia, Askanase Anca, Bae Sang-Cheol, Bernatsky Sasha, Bruce Ian N., Buyon Jill, Clarke Ann E., Dooley Mary Anne, Fortin Paul, Ginzler Ellen, Gladman Dafna, Gordon Caroline, Inanc Murat, Jacobsen Søren, Kalunian Kenneth, Kamen Diane, Khamashta Munther, Lim Sam, Manzi Susan, Merrill Joan, Nived Ola, Peschken Christine, Petri Michelle, Ramsey-Goldman Rosalind, Ruiz-Irastorza Guillermo, Sanchez-Guerrero Jorge, Steinson Kristjan, Sturfelt Gunnar K., van Vollenhoven Ronald, Wallace Daniel J., Zoma Asad, Rahman Anisur Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study Arthritis research & therapy 2017;19 (1):287 [PubMed]
• Levitsky Adrian, Brismar Kerstin, Hafström Ingiäld, Hambardzumyan Karen, Lourdudoss Cecilia, van Vollenhoven Ronald F., Saevarsdottir Saedis Obesity is a strong predictor of worse clinical outcomes and treatment responses in early rheumatoid arthritis: results from the SWEFOT trial RMD open 2017;3 (2):e000458 [PubMed]
• Schiff Michael, Takeuchi Tsutomu, Fleischmann Roy, Gaich Carol L., DeLozier Amy M., Schlichting Douglas, Kuo Wen-Ling, Won Ji-Eon, Carmack Tara, Rooney Terence, Durez Patrick, Shaikh Saeed, Hidalgo Rodolfo Pardo, van Vollenhoven Ronald, Zerbini Cristiano A. F. Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment Arthritis research & therapy 2017;19 (1):208 [PubMed]
• Chatzidionysiou Katerina, Lie Elisabeth, Lukina Galina, Hetland Merete L., Hauge Ellen-Margrethe, Pavelka Karel, Gabay Cem, Scherer Almut, Nordström Dan, Canhao Helena, Santos Maria José, Tomsic Matija, Rotar Ziga, Hernández M. Victoria, Gomez-Reino Juan, Ancuta Ioan, Kvien Tore K., van Vollenhoven Ronald Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration Journal of rheumatology 2017;44 (2):162-169 [PubMed]
• Fleischmann Roy, Wollenhaupt Jürgen, Takiya Liza, Maniccia Anna, Kwok Kenneth, Wang Lisy, van Vollenhoven Ronald F. Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies RMD open 2017;3 (2):e000491 [PubMed]
• Ramiro Sofia, Sepriano Alexandre, Chatzidionysiou Katerina, Nam Jackie L., Smolen Josef S., van der Heijde Désirée, Dougados Maxime, van Vollenhoven Ronald, Bijlsma Johannes W., Burmester Gerd R., Scholte-Voshaar Marieke, Falzon Louise, Landewé Robert B. M. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis Annals of the rheumatic diseases 2017;76 (6):1101-1136 [PubMed]
• Fleischmann Roy, Tongbram Vanita, van Vollenhoven Ronald, Tang Derek H., Chung James, Collier David, Urs Shilpa, Ndirangu Kerigo, Wells George, Pope Janet Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor-methotrexate combination therapy versus triple therapy in rheumatoid arthritis RMD open 2017;3 (1):e000371 [PubMed]
• Lesuis Nienke, den Broeder Nathan, Boers Nadine, Piek Ester, Teerenstra Steven, Hulscher Marlies, van Vollenhoven Ronald, den Broeder Alfons A. The effects of an educational meeting and subsequent computer reminders on the ordering of laboratory tests by rheumatologists: an interrupted time series analysis Clinical and experimental rheumatology 2017;35 (3):379-383 [PubMed]
• Choi M. Y., Clarke A. E., St Pierre Y., Hanly J. G., Urowitz M. B., Romero-Diaz J., Gordon C., Bae S.-C., Bernatsky S., Wallace D. J., Merrill J. T., Isenberg D. A., Rahman A., Ginzler E. M., Petri M., Bruce I. N., Dooley M. A., Fortin P., Gladman D. D., Sanchez-Guerrero J., Steinsson K., Ramsey-Goldman R., Khamashta M. A., Aranow C., Alarcón G. S., Manzi S., Nived O., Zoma A. A., van Vollenhoven R. F., Ramos-Casals M., Ruiz-Irastorza G., Lim S. S., Kalunian K. C., Inanc M., Kamen D. L., Peschken C. A., Jacobsen S., Askanase A., Buyon J., Mahler M., Fritzler M. J. The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients Lupus 2017;26 (10):1051-1059 [PubMed]
• Burmester Gerd R., Rigby William F., van Vollenhoven Ronald F., Kay Jonathan, Rubbert-Roth Andrea, Blanco Ricardo, Kadva Alysha, Dimonaco Sophie Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial Annals of the rheumatic diseases 2017;76 (7):1279-1284 [PubMed]
• Genovese Mark C., Kremer Joel M., van Vollenhoven Ronald F., Alten Rieke, Scali Juan Jose, Kelman Ariella, Dimonaco Sophie, Brockwell Laura Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis Arthritis & rheumatology (Hoboken, N.J.) 2017;69 (9):1751-1761 [PubMed]

2016

• Hanly John G., Su Li, Urowitz Murray B., Romero-Diaz Juanita, Gordon Caroline, Bae Sang-Cheol, Bernatsky Sasha, Clarke Ann E., Wallace Daniel J., Merrill Joan T., Isenberg David A., Rahman Anisur, Ginzler Ellen M., Petri Michelle, Bruce Ian N., Dooley M. A., Fortin Paul, Gladman Dafna D., Sanchez-Guerrero Jorge, Steinsson Kristjan, Ramsey-Goldman Rosalind, Khamashta Munther A., Aranow Cynthia, Alarcón Graciela S., Fessler Barri J., Manzi Susan, Nived Ola, Sturfelt Gunnar K., Zoma Asad A., van Vollenhoven Ronald F., Ramos-Casals Manuel, Ruiz-Irastorza Guillermo, Lim S. Sam, Kalunian Kenneth C., Inanc Murat, Kamen Diane L., Peschken Christine A., Jacobsen Soren, Askanase Anca, Theriault Chris, Farewell Vernon A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach Arthritis & rheumatology (Hoboken, N.J.) 2016;68 (8):1932-1944 [PubMed]
• Rovin Brad H., van Vollenhoven Ronald F., Aranow Cynthia, Wagner Carrie, Gordon Robert, Zhuang Yanli, Belkowski Stanley, Hsu Benjamin A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis Arthritis & rheumatology (Hoboken, N.J.) 2016;68 (9):2174-2183 [PubMed]
• Hambardzumyan Karen, Bolce Rebecca J., Saevarsdottir Saedis, Forslind Kristina, Wallman Johan K., Cruickshank Scott E., Sasso Eric H., Chernoff David, van Vollenhoven Ronald F. Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trial RMD open 2016;2 (1):e000197 [PubMed]
• Kastbom Alf, Forslind Kristina, Ernestam Sofia, Geborek Pierre, Karlsson Johan A., Petersson Ingemar F., Saevarsdottir Saedis, Klareskog Lars, van Vollenhoven Ronald F., Lundberg Karin Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial Annals of the rheumatic diseases 2016;75 (2):356-361 [PubMed]
• Lesuis Nienke, Hulscher Marlies E. J. L., Piek Ester, Demirel Hatice, van der Laan-Baalbergen Nicole, Meek Inger, van Vollenhoven Ronald F., den Broeder Alfons A. Choosing Wisely in Daily Practice: An Intervention Study on Antinuclear Antibody Testing by Rheumatologists Arthritis care & research 2016;68 (4):562-569 [PubMed]
• Lesuis Nienke, Piek Ester, Demirel Hatice, den Broeder Alfons A., Hulscher Marlies E. J. L., Meek Inger, van der Laan-Baalbergen Nicole, van Vollenhoven Ronald F. Choosing Wisely in daily practice: an intervention study on antinuclear antibody testing by rheumatologists. Comment on the article by Lesuis et al Reply Arthritis care & research 2016;68 (7):1051 [PubMed]
• Smolen Josef S., Collaud Basset Sabine, Boers Maarten, Breedveld Ferdinand, Edwards Christopher J., Kvien Tore K., Miossec Pierre, Sokka-Isler Tuulikki, van Vollenhoven Ronald F., Abadie Eric C., Bruyère Olivier, Cooper Cyrus, Mäkinen Heidi, Thomas Thierry, Tugwell Peter, Reginster Jean-Yves Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease Annals of the rheumatic diseases 2016;75 (7):1268-1271 [PubMed]
• van Vollenhoven Ronald F., Petri Michelle, Wallace Daniel J., Roth David A., Molta Charles T., Hammer Anne E., Tang Yongqiang, Thompson April Cumulative Corticosteroid Dose Over Fifty-Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials Arthritis & rheumatology (Hoboken, N.J.) 2016;68 (9):2184-2192 [PubMed]
• Kievit Wietske, van Herwaarden Noortje, van den Hoogen Frank Hj, van Vollenhoven Ronald F., Bijlsma Johannes Wj, van den Bemt Bart Jf, van der Maas Aatke, den Broeder Alfons A. Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study Annals of the rheumatic diseases 2016;75 (11):1939-1944 [PubMed]
• Olofsson Tor, Johansson Kari, Eriksson Jonas K., van Vollenhoven Ronald, Miller Heather, Petersson Ingemar F., Askling Johan, Neovius Martin Does disease activity at start of biologic therapy influence work-loss in RA patients? Rheumatology (Oxford, England) 2016;55 (4):729-734 [PubMed]
• Wadström Hjalmar, Frisell Thomas, Sparén Pär, Askling Johan, Klareskog Lars, Lindblad Staffan, Ernestam Sofia, Feltelius Nils, van Vollenhoven Ronald, Baecklund Eva, Kastbom Alf, Forsblad Helena, Jacobsson Lennart, Geborek Pierre, Kristensen Lars-Erik, Rantapää-Dahlqvist Solbritt Do RA or TNF inhibitors increase the risk of cervical neoplasia or of recurrence of previous neoplasia? A nationwide study from Sweden Annals of the rheumatic diseases 2016;75 (7):1272-1278 [PubMed]
• Levitsky Adrian, Wick Marius C., Möttönen Timo, Leirisalo-Repo Marjatta, Laasonen Leena, Korpela Markku, van Vollenhoven Ronald F., Rantalaiho Vappu Early treatment intensification induces favourable radiographic outcomes according to predicted versus observed radiographic progression in early rheumatoid arthritis: a subanalysis of the randomised FIN-RACo and NEO-RACo trials Clinical and experimental rheumatology 2016;34 (6):1065-1071 [PubMed]
• Gabay Cem, Riek Myriam, Hetland Merete Lund, Hauge Ellen-Margrethe, Pavelka Karel, Tomšič Matija, Canhao Helena, Chatzidionysiou Katerina, Lukina Galina, Nordström Dan C., Lie Elisabeth, Ancuta Ioan, Hernández M. Victoria, van Riel Piet L. M. C., van Vollenhoven Ronald, Kvien Tore K. Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study Annals of the rheumatic diseases 2016;75 (7):1336-1342 [PubMed]
• Chatzidionysiou Katerina, Lie Elisabeth, Nasonov Evgeny, Lukina Galina, Hetland Merete Lund, Tarp Ulrik, Ancuta Ioan, Pavelka Karel, Nordström Dan C., Gabay Cem, Canhão Helene, Tomsic Matija, van Riel Piet L. C. M., Gomez-Reino Juan, Kvien Tore K., van Vollenhoven Ronald F. Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration Arthritis research & therapy 2016;18:50 [PubMed]
• Merrill J. T., van Vollenhoven R. F., Buyon J. P., Furie R. A., Stohl W., Morgan-Cox M., Dickson C., Anderson P. W., Lee C., Berclaz P.-Y., Dörner T. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study Annals of the rheumatic diseases 2016;75 (2):332-340 [PubMed]
• Fleischmann Roy M., Huizinga Tom W. J., Kavanaugh Arthur F., Wilkinson Bethanie, Kwok Kenneth, DeMasi Ryan, van Vollenhoven Ronald F. Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis RMD open 2016;2 (2):e000262 [PubMed]
• Chatzidionysiou Katerina, Lie Elisabeth, Nasonov Evgeny, Lukina Galina, Hetland Merete Lund, Tarp Ulrik, Ancuta Ioan, Pavelka Karel, Nordström Dan C., Gabay Cem, Canhão Helene, Tomsic Matija, van Riel Piet L. C. M., Gomez-Reino Juan, Kvien Tore K., van Vollenhoven Ronald F. Erratum to: Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration Arthritis research & therapy 2016;18 (1):144 [PubMed]
• Stoffer Michaela A., Schoels Monika M., Smolen Josef S., Aletaha Daniel, Breedveld Ferdinand C., Burmester Gerd, Bykerk Vivian, Dougados Maxime, Emery Paul, Haraoui Boulos, Gomez-Reino Juan, Kvien Tore K., Nash Peter, Navarro-Compán Victoria, Scholte-Voshaar Marieke, van Vollenhoven Ronald, van der Heijde Désirée, Stamm Tanja A. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update Annals of the rheumatic diseases 2016;75 (1):16-22 [PubMed]
• van Vollenhoven Ronald F., Østergaard Mikkel, Leirisalo-Repo Marjatta, Uhlig Till, Jansson Marita, Larsson Esbjörn, Brock Fiona, Franck-Larsson Karin Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis Annals of the rheumatic diseases 2016;75 (1):52-58 [PubMed]
• Pope Janet E., Rothfield Naomi F., Ramsey-Goldman Rosalind, Douglas Smith C., Bernatsky Sasha R., Furie Richard A., Hudson Marie, Burgos-Vargas Ruben, Senécal Jean-Luc, Inanç Murat, van Vollenhoven Ronald F., Chandran Vinod, Nash Peter T., Muangchan Chayawee Hydroxychloroquine in systemic lupus erythematosus: comment on the article by Muangchan et al Reply Arthritis care & research 2016;68 (7):1053-1054 [PubMed]
• Emamikia Sharzad, Arkema Elizabeth V., Györi Noémi, Detert Jacqueline, Chatzidionysiou Katerina, Dougados Maxime, Burmester Gerd Rüdiger, van Vollenhoven Ronald Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials RMD open 2016;2 (2):e000323 [PubMed]
• Eriksson Jonas K., Wallman Johan K., Miller Heather, Petersson Ingemar F., Ernestam Sofia, Vivar Nancy, van Vollenhoven Ronald F., Neovius Martin Infliximab Versus Conventional Combination Treatment and Seven-Year Work Loss in Early Rheumatoid Arthritis: Results of a Randomized Swedish Trial Arthritis care & research 2016;68 (12):1758-1766 [PubMed]
• Rubbert-Roth Andrea, Sebba Anthony, Brockwell Laura, Kelman Ariella, Porter-Brown Benjamin, Pulley Jennifer, Napalkov Pavel, van Vollenhoven Ronald F. Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab RMD open 2016;2 (1):e000213 [PubMed]
• van Vollenhoven Ronald F. New therapeutic approaches in rheumatoid arthritis Presse medicale (Paris, France 2016;45 (6 Part 2):e179-e192 [PubMed]
• Rydén-Aulin Monica, Boumpas Dimitrios, Bultink Irene, Callejas Rubio Jose Luis, Caminal-Montero Luis, Castro Antoni, Colodro Ruiz Agustín, Doria Andrea, Dörner Thomas, Gonzalez-Echavarri Cristina, Gremese Elisa, Houssiau Frederic A., Huizinga Tom, Inanç Murat, Isenberg David, Iuliano Annamaria, Jacobsen Søren, Jimenéz-Alonso Juan, Kovács Lászlo, Mariette Xavier, Mosca Marta, Nived Ola, Oristrell Joaquim, Ramos-Casals Manuel, Rascón Javier, Ruiz-Irastorza Guillermo, Sáez-Comet Luis, Salvador Cervelló Gonzalo, Sebastiani Gian Domenico, Squatrito Danilo, Szücs Gabriella, Voskuyl Alexandre, van Vollenhoven Ronald Off-label use of rituximab for systemic lupus erythematosus in Europe Lupus science & medicine 2016;3 (1):e000163 [PubMed]
• Lesuis N., den Broeder A. A., Hulscher M. E. J. L., van Vollenhoven R. F. Practice what you preach? An exploratory multilevel study on rheumatoid arthritis guideline adherence by rheumatologists RMD open 2016;2 (1):e000195 [PubMed]
• Walker Ulrich A., Jaeger Veronika K., Chatzidionysiou Katerina, Hetland Merete L., Hauge Ellen-Margrethe, Pavelka Karel, Nordström Dan C., Canhão Helena, Tomšič Matija, van Vollenhoven Ronald, Gabay Cem Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis Rheumatology (Oxford, England) 2016;55 (2):230-236 [PubMed]
• Quattrocchi Emilia, Østergaard Mikkel, Taylor Peter C., van Vollenhoven Ronald F., Chu Myron, Mallett Stephen, Perry Hayley, Kurrasch Regina Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials PLoS ONE 2016;11 (6):e0157961 [PubMed]
• Kahl L., Patel J., Layton M., Binks M., Hicks K., Leon G., Hachulla E., Machado D., Staumont-Sallé D., Dickson M., Condreay L., Schifano L., Zamuner S., van Vollenhoven R. F. Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus Lupus 2016;25 (13):1420-1430 [PubMed]
• Genovese Mark C., van Vollenhoven Ronald F., Wilkinson Bethanie, Wang Lisy, Zwillich Samuel H., Gruben David, Biswas Pinaki, Riese Richard, Takiya Liza, Jones Thomas V. Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis Arthritis research & therapy 2016;18:145 [PubMed]
• Hanly John G., O'Keeffe Aidan G., Su Li, Urowitz Murray B., Romero-Diaz Juanita, Gordon Caroline, Bae Sang-Cheol, Bernatsky Sasha, Clarke Ann E., Wallace Daniel J., Merrill Joan T., Isenberg David A., Rahman Anisur, Ginzler Ellen M., Fortin Paul, Gladman Dafna D., Sanchez-Guerrero Jorge, Petri Michelle, Bruce Ian N., Dooley Mary Anne, Ramsey-Goldman Rosalind, Aranow Cynthia, Alarcón Graciela S., Fessler Barri J., Steinsson Kristjan, Nived Ola, Sturfelt Gunnar K., Manzi Susan, Khamashta Munther A., van Vollenhoven Ronald F., Zoma Asad A., Ramos-Casals Manuel, Ruiz-Irastorza Guillermo, Lim S. Sam, Stoll Thomas, Inanc Murat, Kalunian Kenneth C., Kamen Diane L., Maddison Peter, Peschken Christine A., Jacobsen Soren, Askanase Anca, Theriault Chris, Thompson Kara, Farewell Vernon The frequency and outcome of lupus nephritis: results from an international inception cohort study Rheumatology (Oxford, England) 2016;55 (2):252-262 [PubMed]
• Burmester Gerd R., Rigby William F., van Vollenhoven Ronald F., Kay Jonathan, Rubbert-Roth Andrea, Kelman Ariella, Dimonaco Sophie, Mitchell Nina Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial Annals of the rheumatic diseases 2016;75 (6):1081-1091 [PubMed]
• Strand Vibeke, van Vollenhoven Ronald F., Lee Eun Bong, Fleischmann Roy, Zwillich Samuel H., Gruben David, Koncz Tamas, Wilkinson Bethanie, Wallenstein Gene Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis Rheumatology (Oxford, England) 2016;55 (6):1031-1041 [PubMed]
• Smolen Josef S., Breedveld Ferdinand C., Burmester Gerd R., Bykerk Vivian, Dougados Maxime, Emery Paul, Kvien Tore K., Navarro-Compán M. Victoria, Oliver Susan, Schoels Monika, Scholte-Voshaar Marieke, Stamm Tanja, Stoffer Michaela, Takeuchi Tsutomu, Aletaha Daniel, Andreu Jose Louis, Aringer Martin, Bergman Martin, Betteridge Neil, Bijlsma Hans, Burkhardt Harald, Cardiel Mario, Combe Bernard, Durez Patrick, Fonseca Joao Eurico, Gibofsky Alan, Gomez-Reino Juan J., Graninger Winfried, Hannonen Pekka, Haraoui Boulos, Kouloumas Marios, Landewe Robert, Martin-Mola Emilio, Nash Peter, Ostergaard Mikkel, Östör Andrew, Richards Pam, Sokka-Isler Tuulikki, Thorne Carter, Tzioufas Athanasios G., van Vollenhoven Ronald, de Wit Martinus, van der Heijde Desirée Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force Annals of the rheumatic diseases 2016;75 (1):3-15 [PubMed]
• Genovese Mark C., van Vollenhoven Ronald F., Pacheco-Tena César, Zhang Yanqiong, Kinnman Nils VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis Arthritis & rheumatology (Hoboken, N.J.) 2016;68 (1):46-55 [PubMed]

2015

• van Herwaarden Noortje, Bouman Chantal A. M., van der Maas Aatke, van Vollenhoven Ronald F., Bijlsma Johannes W., van den Hoogen Frank H. J., den Broeder Alfons A., van den Bemt Bart J. F. Adalimumab and etanercept serum (anti)drug levels are not predictive for successful dose reduction or discontinuation in rheumatoid arthritis Annals of the rheumatic diseases 2015;74 (12):2260-+ [PubMed]
• Orbai A.-M., Truedsson L., Sturfelt G., Nived O., Fang H., Alarcón G. S., Gordon C., Merrill Jt, Fortin P. R., Bruce I. N., Isenberg D. A., Wallace D. J., Ramsey-Goldman R., Bae S.-C., Hanly J. G., Sanchez-Guerrero J., Clarke A. E., Aranow C. B., Manzi S., Urowitz M. B., Gladman D. D., Kalunian K. C., Costner M. I., Werth V. P., Zoma A., Bernatsky S., Ruiz-Irastorza G., Khamashta M. A., Jacobsen S., Buyon J. P., Maddison P., Dooley M. A., van Vollenhoven R. F., Ginzler E., Stoll T., Peschken C., Jorizzo J. L., Callen J. P., Lim S. S., Fessler B. J., Inanc M., Kamen D. L., Rahman A., Steinsson K., Franks A. G., Sigler L., Hameed S., Pham N., Brey R., Weisman M. H., McGwin G., Magder L. S., Petri M. Anti-C1q antibodies in systemic lupus erythematosus Lupus 2015;24 (1):42-49 [PubMed]
• Arkema Elizabeth V., Jonsson Jerker, Baecklund Eva, Bruchfeld Judith, Feltelius Nils, Askling Johan, Cöster Lars, Forsblad Helena, Geborek Peirre, Jacobsson Lennart, Klarskog Lars, Kristensen Lars-Erik, Lindblad Staffan, Rantapää-Dahlqvist Solbritt, van Vollenhoven Ronald Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments? Annals of the rheumatic diseases 2015;74 (6):1212-1217 [PubMed]
• Smolen Josef S., van Vollenhoven Ronald, Kavanaugh Arthur, Strand Vibeke, Vencovsky Jiri, Schiff Michael, Landewé Robert, Haraoui Boulos, Arendt Catherine, Mountian Irina, Carter David, van der Heijde Désirée Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients Arthritis research & therapy 2015;17 (1):245 [PubMed]
• Kievit W., van Herwaarden N., van den Hoogen F., van Vollenhoven R., Bijlsma H., van den Bemt B., van der Maas A., den Broeder A. Controlling the Cost Spent on Expensive Biologic Agents: an Example of Net Monetary Savings By Dose Optimisation of Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis Patients Value in health 2015;18 (7):A647-A648 [PubMed]
• Eriksson Jonas K., Karlsson Johan A., Bratt Johan, Petersson Ingemar F., van Vollenhoven Ronald F., Ernestam Sofia, Geborek Pierre, Neovius Martin Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial Annals of the rheumatic diseases 2015;74 (6):1094-1101 [PubMed]
• Saevarsdottir Saedis, Rezaei Hamed, Geborek Pierre, Petersson Ingemar, Ernestam Sofia, Albertsson Kristina, Forslind Kristina, van Vollenhoven Ronald F. Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial Annals of the rheumatic diseases 2015;74 (8):1509-1514 [PubMed]
• Kisten Yogan, Györi Noémi, Af Klint Erik, Rezaei Hamed, Levitsky Adrian, Karlsson Anna, van Vollenhoven Ronald Detection of clinically manifest and silent synovitis in the hands and wrists by fluorescence optical imaging RMD open 2015;1 (1):e000106 [PubMed]
• van Herwaarden Noortje, van der Maas Aatke, Minten Michiel J. M., van den Hoogen Frank H. J., Kievit Wietske, van Vollenhoven Ronald F., Bijlsma Johannes W. J., van den Bemt Bart J. F., den Broeder Alfons A. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial BMJ (Clinical research ed.) 2015;350:h1389 [PubMed]
• Johansson Kari, Eriksson Jonas K., van Vollenhoven Ronald, Miller Heather, Askling Johan, Neovius Martin Does disease activity at the start of biologic therapy influence health care costs in patients with RA? Rheumatology (Oxford, England) 2015;54 (8):1472-1477 [PubMed]
• van Vollenhoven R. F., Layton M., Kahl L., Schifano L., Hachulla E., Machado D., Staumont-Sallé D., Patel J. DRESS syndrome and reversible liver function abnormalities in patients with systemic lupus erythematosus treated with the highly selective JAK-1 inhibitor GSK2586184 Lupus 2015;24 (6):648-649 [PubMed]
• Chatzidionysiou K., Kristensen L.-E., Eriksson J., Askling J., van Vollenhoven R. Effectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish register Scandinavian journal of rheumatology 2015;44 (6):431-437 [PubMed]
• Chatzidionysiou Katerina, Askling Johan, Eriksson Jonas, Kristensen Lars Erik, van Vollenhoven Ronald Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register Annals of the rheumatic diseases 2015;74 (5):890-896 [PubMed]
• Smolen Josef S., Weinblatt Michael E., van der Heijde Désirée, Rigby William F. C., van Vollenhoven Ronald, Bingham Clifton O., Veenhuizen Melissa, Gill Anne, Zhao Fangyi, Komocsar Wendy J., Berclaz Pierre-Yves, Ortmann Robert, Lee Chin Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study Annals of the rheumatic diseases 2015;74 (8):1567-1570 [PubMed]
• van Vollenhoven Ronald F., Bolce Rebecca, Hambardzumyan Karen, Saevarsdottir Saedis, Forslind Kristina, Petersson Ingemar F., Sasso Eric H., Hwang C. C., Segurado Oscar G., Geborek Pierre Enhancement of Patient Recruitment in Rheumatoid Arthritis Clinical Trials Using a Multi-Biomarker Disease Activity Score as an Inclusion Criterion Arthritis & rheumatology (Hoboken, N.J.) 2015;67 (11):2855-2860 [PubMed]
• Bruce Ian N., O'Keeffe Aidan G., Farewell Vern, Hanly John G., Manzi Susan, Su Li, Gladman Dafna D., Bae Sang-Cheol, Sanchez-Guerrero Jorge, Romero-Diaz Juanita, Gordon Caroline, Wallace Daniel J., Clarke Ann E., Bernatsky Sasha, Ginzler Ellen M., Isenberg David A., Rahman Anisur, Merrill Joan T., Alarcón Graciela S., Fessler Barri J., Fortin Paul R., Petri Michelle, Steinsson Kristjan, Dooley Mary Anne, Khamashta Munther A., Ramsey-Goldman Rosalind, Zoma Asad A., Sturfelt Gunnar K., Nived Ola, Aranow Cynthia, Mackay Meggan, Ramos-Casals Manuel, van Vollenhoven Ronald F., Kalunian Kenneth C., Ruiz-Irastorza Guillermo, Lim Sam, Kamen Diane L., Peschken Christine A., Inanc Murat, Urowitz Murray B. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort Annals of the rheumatic diseases 2015;74 (9):1706-1713 [PubMed]
• Parker Ben, Urowitz Murray B., Gladman Dafna D., Lunt Mark, Donn Rachelle, Bae Sang-Cheol, Sanchez-Guerrero Jorge, Romero-Diaz Juanita, Gordon Caroline, Wallace Daniel J., Clarke Ann E., Bernatsky Sasha, Ginzler Ellen M., Isenberg David A., Rahman Anisur, Merrill Joan T., Alarcón Graciela S., Fessler Barri J., Fortin Paul R., Hanly John G., Petri Michelle, Steinsson Kristjan, Dooley Mary Anne, Manzi Susan, Khamashta Munther A., Ramsey-Goldman Rosalind, Zoma Asad A., Sturfelt Gunnar K., Nived Ola, Aranow Cynthia, Mackay Meggan, Ramos-Casals Manuel, van Vollenhoven Ronald F., Kalunian Kenneth C., Ruiz-Irastorza Guillermo, Lim S. Sam, Kamen Diane L., Peschken Christine A., Inanc Murat, Bruce Ian N. Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort Annals of the rheumatic diseases 2015;74 (8):1530-1536 [PubMed]
• van Herwaarden Noortje Individualised biological treatment in rheumatoid arthritis 2015. 181p. ISBN 9789461825216. [UvA Dissertations Online] Universiteit Utrecht: Geneeskunde. (Supervisors: Bijlsma J. W. J., van Vollenhoven R. F.; Co-supervisors: van der Maas A., van den Bemt B. J. F.)
• van Vollenhoven Ronald F., Fleischmann Roy M., Furst Daniel E., Lacey Stuart, Lehane Patricia B. Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years Journal of rheumatology 2015;42 (10):1761-1766 [PubMed]
• Hanly John G., Su Li, Urowitz Murray B., Romero-Diaz Juanita, Gordon Caroline, Bae Sang-Cheol, Bernatsky Sasha, Clarke Ann E., Wallace Daniel J., Merrill Joan T., Isenberg David A., Rahman Anisur, Ginzler Ellen M., Petri Michelle, Bruce Ian N., Dooley M. A., Fortin Paul, Gladman Dafna D., Sanchez-Guerrero Jorge, Steinsson Kristjan, Ramsey-Goldman Rosalind, Khamashta Munther A., Aranow Cynthia, Alarcón Graciela S., Fessler Barri J., Manzi Susan, Nived Ola, Sturfelt Gunnar K., Zoma Asad A., van Vollenhoven Ronald F., Ramos-Casals Manuel, Ruiz-Irastorza Guillermo, Lim S. Sam, Kalunian Kenneth C., Inanc Murat, Kamen Diane L., Peschken Christine A., Jacobsen Soren, Askanase Anca, Theriault Chris, Thompson Kara, Farewell Vernon Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study Arthritis & rheumatology (Hoboken, N.J.) 2015;67 (7):1837-1847 [PubMed]
• Levitsky A., Forslind K., van Vollenhoven R. F. Predicted vs. observed radiographic progression in early rheumatoid arthritis (POPeRA): results from a randomized trial Scandinavian journal of rheumatology 2015;44 (5):348-353 [PubMed]
• Hambardzumyan Karen, Bolce Rebecca, Saevarsdottir Saedis, Cruickshank Scott E., Sasso Eric H., Chernoff David, Forslind Kristina, Petersson Ingemar F., Geborek Pierre, van Vollenhoven Ronald F. Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial Annals of the rheumatic diseases 2015;74 (6):1102-1109 [PubMed]
• van Vollenhoven Ronald F., Voskuyl Alexandre, Morand Eric, Aranow Cynthia Remission in SLE: closing in on the target Annals of the rheumatic diseases 2015;74 (12):2103-2106 [PubMed]
• van Vollenhoven R. F., Wax S., Li Y., Tak P. P. Safety and efficacy of atacicept in combination with rituximab for reducing the signs and symptoms of rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled pilot trial Arthritis & rheumatology (Hoboken, N.J.) 2015;67 (11):2828-2836 [PubMed]
• Hui-Yuen Joyce S., Reddy Arthi, Taylor Jennifer, Li Xiaoqing, Eichenfield Andrew H., Bermudez Liza M., Starr Amy J., Imundo Lisa F., Buyon Jill, Furie Richard A., Kamen Diane L., Manzi Susan, Petri Michelle, Ramsey-Goldman Rosalind, van Vollenhoven Ronald F., Wallace Daniel J., Askanase Anca Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices Journal of rheumatology 2015;42 (12):2288-2295 [PubMed]
• Levitsky Adrian, Erlandsson Malin C., van Vollenhoven Ronald F., Bokarewa Maria I. Serum survivin predicts responses to treatment in active rheumatoid arthritis: a post hoc analysis from the SWEFOT trial BMC medicine 2015;13:247 [PubMed]
• Nagy György, van Vollenhoven Ronald F. Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now? Arthritis research & therapy 2015;17:181 [PubMed]
• Lie Elisabeth, Kristensen Lars Erik, Forsblad-d'Elia Helena, Zverkova-Sandström Tatiana, Askling Johan, Jacobsson Lennart T., Baecklund Eva, Feltelius Nils, Kastbom Alf, Klareskog Lars, Rantapää-Dahlqvist Solbritt, van Vollenhoven Ronald The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study Annals of the rheumatic diseases 2015;74 (6):970-978 [PubMed]
• Mariette X., Vencovsky J., Lortholary O., Gomez-Reino J., de Longueville M., Ralston P., Weinblatt M., van Vollenhoven R. The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region RMD open 2015;1 (1):e000044 [PubMed]
• Raaschou Pauline, Frisell Thomas, Askling Johan, Baecklund Eva, Kastbom Alf, Forsblad Helena, Feltelius Nils, Geborek Pierre, Jacobsson Lennart, Klareskog Lars, Lindblad Staffan, Rantapaa-Dahlqvist Solbritt, Kristensen Lars-Erik, van Vollenhoven Ronald TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study Annals of the rheumatic diseases 2015;74 (12):2137-2143 [PubMed]
• Muangchan Chayawee, van Vollenhoven Ronald F., Bernatsky Sasha R., Smith C. Douglas, Hudson Marie, Inanç Murat, Rothfield Naomi F., Nash Peter T., Furie Richard A., Senécal Jean-Luc, Chandran Vinod, Burgos-Vargas Ruben, Ramsey-Goldman Rosalind, Pope Janet E. Treatment Algorithms in Systemic Lupus Erythematosus Arthritis care & research 2015;67 (9):1237-1245 [PubMed]
• Weinblatt Michael E., Fleischmann Roy, van Vollenhoven Ronald F., Emery Paul, Huizinga Tom Wj, Cutolo Maurizio, van der Heijde Désirée, Duncan Benjamin, Davies Owen, Luijtens Kristel, Dougados Maxime Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population Arthritis research & therapy 2015;17 (1):325 [PubMed]
• Bykerk V. P., Cush J., Winthrop K., Calabrese L., Lortholary O., de Longueville M., van Vollenhoven R., Mariette X. Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials Annals of the rheumatic diseases 2015;74 (1):96-103 [PubMed]

2014

• Lertratanakul Apinya, Wu Peggy, Dyer Alan, Urowitz Murray, Gladman Dafna, Fortin Paul, Bae Sang-Cheol, Gordon Caroline, Clarke Ann, Bernatsky Sasha, Hanly John G., Isenberg David, Rahman Anisur, Merrill Joan, Wallace Daniel J., Ginzler Ellen, Khamashta Munther, Bruce Ian, Nived Ola, Sturfelt Gunnar, Steinsson Kristjan, Manzi Susan, Dooley Mary Anne, Kalunian Kenneth, Petri Michelle, Aranow Cynthia, Font Josep, van Vollenhoven Ronald, Stoll Thomas, Ramsey-Goldman Rosalind 25-Hydroxyvitamin D and Cardiovascular Disease in Patients With Systemic Lupus Erythematosus: Data From a Large International Inception Cohort Arthritis care & research 2014;66 (8):1167-1176 [PubMed]
• Smolen Josef S., Emery Paul, Fleischmann Roy, van Vollenhoven Ronald F., Pavelka Karel, Durez Patrick, Guérette Benoît, Kupper Hartmut, Redden Laura, Arora Vipin, Kavanaugh Arthur Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial Lancet 2014;383 (9914):321-332 [PubMed]
• Vivar Nancy, van Vollenhoven Ronald F. Advances in the treatment of rheumatoid arthritis F1000prime reports 2014;6:31 [PubMed]
• Urowitz Murray B., Gladman Dafna D., Ibañez Dominique, Sanchez-Guerrero Jorge, Romero-Diaz Juanita, Gordon Caroline, Bae Sang-Cheol, Clarke Anne E., Bernatsky Sasha, Fortin Paul R., Hanly John G., Isenberg David, Rahman Anisur, Wallace Daniel J., Ginzler Ellen, Petri Michelle, Bruce Ian N., Merrill Joan T., Nived Ola, Sturfelt Gunnar, Dooley Mary Anne, Alarcón Graciela S., Fessler Barri, Steinsson Kristjan, Ramsey-Goldman Rosalind, Zoma Asad, Khamashta Munther, Manzi Susan, van Vollenhoven Ronald, Ramos-Casals Manuel, Aranow Cynthia, Stoll Thomas American College of Rheumatology Criteria at Inception, and Accrual over 5 Years in the SLICC Inception Cohort Journal of rheumatology 2014;41 (5):875-880 [PubMed]
• Chatzidionysiou Katerina Biological therapy in rheumatoid arthritis - epidemiological studies 2014. 76p. ISBN 9789175495613. [UvA Dissertations Online] Karolinska Institute, Stockholm, Sweden: Unit for clinical thearpy research inflammatory diseases (ClinTRID). (Supervisor: van Vollenhoven R.; Co-supervisor: Askling J.)
• Urowitz M., Gladman D. D., Ibañez D., Sanchez-Guerrero J., Bae S. C., Gordon C., Fortin P. R., Clarke A., Bernatsky S., Hanly J. G., Wallace D. J., Isenberg D., Rahman A., Merrill J., Ginzler E., Alarcón G. S., Fessler B., Khamashta M., Steinsson K., Petri M., Dooley M., Bruce I. N., Manzi S., Sturfelt G., Nived O., Ramsey-Goldman R., Zoma A., Maddison P., Kalunian K., van Vollenhoven R., Aranow C., Romero Diaz J., Stoll T. Changes in Quality of Life in the First 5 Years of Disease in a Multicenter Cohort of Patients With Systemic Lupus Erythematosus Arthritis care & research 2014;66 (9):1374-1379 [PubMed]
• Rezaei Hamed, Torp-Pedersen Søren, Af Klint Erik, Backheden Magnus, Kisten Yogan, Györi Noémi, van Vollenhoven Ronald F. Diagnostic utility of musculoskeletal ultrasound in patients with suspected arthritis - a probabilistic approach Arthritis research & therapy 2014;16 (5):448 [PubMed]
• van Herwaarden N., Herfkens-Hol S., van der Maas A., van den Bemt B. J. F., van Vollenhoven R. F., Bijlsma J. W. J., den Broeder A. A. Dose reduction of tocilizumab in rheumatoid arthritis patients with low disease activity Clinical and experimental rheumatology 2014;32 (3):390-394 [PubMed]
• van Herwaarden Noortje, den Broeder Alfons A., Jacobs Wilco, van der Maas Aatke, Bijlsma Johannes W. J., van Vollenhoven Ronald F., van den Bemt Bart J. F. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity Cochrane database of systematic reviews (Online) 2014;2014 (9):CD010455 [PubMed]
• van Vollenhoven Ronald F., Nagy György, Tak Paul P. Early start and stop of biologics: has the time come? BMC medicine 2014;12 (1):25 [PubMed]
• Buyon Jill, van Vollenhoven Ronald Editorial Lupus science & medicine 2014;1 (1):e000028 [PubMed]
• Askling Helena H., Rombo Lars, van Vollenhoven Ronald, Hallén Ingemar, Thörner Åke, Nordin Margareta, Herzog Christian, Kantele Anu Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis: A prospective, open-label, multi-centre study Travel medicine and infectious disease 2014;12 (2):134-142 [PubMed]
• Keystone Edward, Landewé Robert, van Vollenhoven Ronald, Combe Bernard, Strand Vibeke, Mease Philip, Shaughnessy Laura, VanLunen Brenda, van der Heijde Désirée Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension Annals of the rheumatic diseases 2014;73 (12):2094-2100 [PubMed]
• Buyon Jill, van Vollenhoven Ronald Lupus Science and Medicine: the Editors present highlights for the bedside and for the bench in the inaugural issue Lupus science & medicine 2014;1 (1):e000033 [PubMed]
• Pieper J., Johansson S., Snir O., Linton L., Rieck M., Buckner J. H., Winqvist O., van Vollenhoven R., Malmström V. Peripheral and Site-Specific CD4(+)CD28(null) T Cells from Rheumatoid Arthritis Patients Show Distinct Characteristics Scandinavian journal of immunology 2014;79 (2):149-155 [PubMed]
• Petri Michelle A., van Vollenhoven Ronald F., Buyon Jill, Levy Roger A., Navarra Sandra V., Cervera Ricard, Zhong Z. John, Freimuth William W. Relevance of different results of different anti-double-stranded DNA assays in reporting clinical studies: comment on the article by Petri et al Reply Arthritis & rheumatology (Hoboken, N.J.) 2014;66 (2):480 [PubMed]
• van Vollenhoven Ronald, Hambardzumyan Karen, Chernoff David, Bolce Rebecca Response to: 'MBDA: what is it good for?' by Yazici et al Annals of the rheumatic diseases 2014;73 (11):E73 [PubMed]
• Ekö Sara Linder, van Vollenhoven Ronald F. Rituximab and Lupus - A Promising Pair? Current rheumatology reports 2014;16 (9):444 [PubMed]
• Westhovens R., van Vollenhoven R. F., Boumpas D. T., Brzosko M., Svensson K., Bjorneboe O., Meeuwisse C. M., Srinivasan S., Gaudin P., Smolen J. S., Rahman M. U., Nelissen R. L., Vastesaeger N. The early clinical course of infliximab treatment in rheumatoid arthritis: results from the REMARK observational study Clinical and experimental rheumatology 2014;32 (3):315-323 [PubMed]
• Rezaei Hamed The role of X-ray imaging and musculoskeletal ultrasound in the diagnosis and management of rheumatoid arthritis 2014. 70p. ISBN 9789175496801. [UvA Dissertations Online] Karolinska Institute, Stockholm, Sweden: Unit for clinical therapy research inflammatory diseases (ClinTRID). (Supervisor: van Vollenhoven R.; Co-supervisors: Catrina A. I., af Klint E., Saevarsdottir S.)
• Lee Eun Bong, Fleischmann Roy, Hall Stephen, Wilkinson Bethanie, Bradley John D., Gruben David, Koncz Tamas, Krishnaswami Sriram, Wallenstein Gene V., Zang Chuanbo, Zwillich Samuel H., van Vollenhoven Ronald F., Lue Cummins, Schnitz William Martin, Baraf Herbert Stuart Block, Bolster Marcy Behar, Kivitz Alan Jan, Kimmel Steven Charles, Fudman Edward Joel, Quaidoo Emmanuel Adolphus, Churchill Melvin Albert, Birbara Charles Allen, Longley Selden, Stohl William, Niemer Mark William, Payne Dayton Dennis, Kaine Jeffrey Louis, Kafka Shelly Pearl, Fleischmann Roy Mitchell, Charles-Schoeman Christina Marie, Kavanaugh Arthur Francis, Kremer Joel Marc, Ritter Jeffrey Sanders, Stack Michael Thomas, Barron Melanie Creech, Aelion Jacob Asher, Griffin Robert Michael, Peng Stanford Lee-Yu, Walsh Bridget Tyrell, Silverfield Joel Charles, Ghirlanda Mariano Ricardo, Tate Guillermo A., Citera Gustavo, Ximenes Antonio Carlos, Radominski Sebastiao Cezar, Keiserman Mauro W., Zerbini Cristiano Augusto de Freitas, Calabresse Renato Jimenez, Cabezas Pedro Claudio Miranda, Ponce Lucia Tofacitinib versus Methotrexate in Rheumatoid Arthritis New England journal of medicine 2014;370 (25):2377-2386 [PubMed]
• Wilkinson Bethanie, Krishnaswami Sriram, van Vollenhoven Ronald F. Tofacitinib versus Methotrexate in Rheumatoid Arthritis REPLY New England journal of medicine 2014;371 (12):1164-1165 [PubMed]
• van Vollenhoven Ronald F., Mosca Marta, Bertsias George, Isenberg David, Kuhn Annegret, Lerstrøm Kirsten, Aringer Martin, Bootsma Hendrika, Boumpas Dimitrios, Bruce Ian N., Cervera Ricard, Clarke Ann, Costedoat-Chalumeau Nathalie, Czirják László, Derksen Ronald, Dörner Thomas, Gordon Caroline, Graninger Winfried, Houssiau Frédéric, Inanc Murat, Jacobsen Søren, Jayne David, Jedryka-Goral Anna, Levitsky Adrian, Levy Roger, Mariette Xavier, Morand Eric, Navarra Sandra, Neumann Irmgard, Rahman Anisur, Rovensky Jozef, Smolen Josef, Vasconcelos Carlos, Voskuyl Alexandre, Voss Anne, Zakharova Helena, Zoma Asad, Schneider Matthias Treat-to-target in systemic lupus erythematosus: recommendations from an international task force Annals of the rheumatic diseases 2014;73 (6):958-967 [PubMed]

2013

• Karlsson Johan A., Neovius Martin, Nilsson Jan-Åke, Petersson Ingemar F., Bratt Johan, van Vollenhoven Ronald F., Ernestam Sofia, Geborek Pierre Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial Annals of the rheumatic diseases 2013;72 (12):1927-1933 [PubMed]
• Smolen Josef S., van der Heijde Désirée M., Keystone Edward C., van Vollenhoven Ronald F., Goldring Mary B., Guérette Benoît, Cifaldi Mary A., Chen Naijun, Liu Shufang, Landewé Robert B. M. Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate Annals of the rheumatic diseases 2013;72 (7):1156-1162 [PubMed]
• Petri Michelle A., van Vollenhoven Ronald F., Buyon Jill, Levy Roger A., Navarra Sandra V., Cervera Ricard, Zhong Z. John, Freimuth William W. Baseline Predictors of Systemic Lupus Erythematosus Flares: Data From the Combined Placebo Groups in the Phase III Belimumab Trials Arthritis and rheumatism 2013;65 (8):2143-2153 [PubMed]
• van Vollenhoven R. F. B-cell-directed therapies in systemic lupus erythematosus - where do we stand? FOREWORD Lupus 2013;22 (4):341 [PubMed]
• Eriksson Jonas K., Neovius Martin, Bratt Johan, Petersson Ingemar F., van Vollenhoven Ronald F., Geborek Pierre, Ernestam Sofia Biological vs Conventional Combination Treatment and Work Loss in Early Rheumatoid Arthritis A Randomized Trial JAMA internal medicine 2013;173 (15):1407-1414 [PubMed]
• van Vollenhoven Ronald F., Parodis Ioannis, Levitsky Adrian Biologics in SLE: Towards new approaches Best practice & research. Clinical rheumatology 2013;27 (3):341-349 [PubMed]
• van Vollenhoven Ronald F. Case 16-2013: A Girl with Irritability, Hypersomnia, and Somatic Symptoms New England journal of medicine 2013;369 (12):1174 [PubMed]
• van Vollenhoven Ronald F. Challenges and opportunities in SLE clinical trials Current opinion in rheumatology 2013;25 (5):606-615 [PubMed]
• Parker Ben, Urowitz Murray B., Gladman Dafna D., Lunt Mark, Bae Sang-Cheol, Sanchez-Guerrero Jorge, Romero-Diaz Juanita, Gordon Caroline, Wallace Daniel J., Clarke Ann E., Bernatsky Sasha, Ginzler Ellen M., Isenberg David A., Rahman Anisur, Merrill Joan T., Alarcón Graciela S., Fessler Barri J., Fortin Paul R., Hanly John G., Petri Michelle, Steinsson Kristjan, Dooley Mary-Anne, Manzi Susan, Khamashta Munther A., Ramsey-Goldman Rosalind, Zoma Asad A., Sturfelt Gunnar K., Nived Ola, Aranow Cynthia, Mackay Meggan, Ramos-Casals Manuel, van Vollenhoven Raymond F., Kalunian Kenneth C., Ruiz-Irastorza Guillermo, Lim Sam, Kamen Diane L., Peschken Christine A., Inanc Murat, Bruce Ian N. Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort Annals of the rheumatic diseases 2013;72 (8):1308-1314 [PubMed]
• Pieper Jennifer, Herrath Jessica, Raghavan Sukanya, Muhammad Khalid, Vollenhoven Ronald Van, Malmström Vivianne CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients BMC immunology 2013;14:34 [PubMed]
• den Broeder Alfons A., van Herwaarden Noortje, van der Maas Aatke, van den Hoogen Frank H. J., Bijlsma Johannes W., van Vollenhoven Ronald F., van den Bemt Bart J. F. Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study BMC musculoskeletal disorders 2013;14 (1):299 [PubMed]
• Rezaei Hamed, Saevarsdottir Saedis, Geborek Pierre, Petersson Ingemar F., van Vollenhoven Ronald F., Forslind Kristina Evaluation of hand bone loss by digital X-ray radiogrammetry as a complement to clinical and radiographic assessment in early rheumatoid arthritis: results from the SWEFOT trial BMC musculoskeletal disorders 2013;14:79 [PubMed]
• Waldheim E., Elkan A.-C., Bergman S., Frostegård J., van Vollenhoven R., Henriksson E. Welin Extent and characteristics of self-reported pain in patients with systemic lupus erythematosus Lupus 2013;22 (2):136-143 [PubMed]
• Hanly John G., Urowitz Murray B., O'Keeffe Aidan G., Gordon Caroline, Bae Sang-Cheol, Sanchez-Guerrero Jorge, Romero-Diaz Juanita, Clarke Ann E., Bernatsky Sasha, Wallace Daniel J., Ginzler Ellen M., Isenberg David A., Rahman Anisur, Merrill Joan T., Petri Michelle, Fortin Paul R., Gladman Dafna D., Fessler Barri J., Alarcón Graciela S., Bruce Ian N., Dooley Mary Anne, Steinsson Kristjan, Khamashta Munther A., Ramsey-Goldman Rosalind, Manzi Susan, Sturfelt Gunnar K., Nived Ola, Zoma Asad A., van Vollenhoven Ronald F., Ramos-Casals Manuel, Aranow Cynthia, Mackay Meggan, Ruiz-Irastorza Guillermo, Kalunian Kenneth C., Lim S. Sam, Inanc Murat, Kamen Diane L., Peschken Christine A., Jacobsen Soren, Theriault Chris, Thompson Kara, Farewell Vernon Headache in Systemic Lupus Erythematosus Results From a Prospective, International Inception Cohort Study Arthritis and rheumatism 2013;65 (11):2887-2897 [PubMed]
• Waldheim E., Elkan A.-C., Pettersson S., van Vollenhoven R., Bergman S., Frostegård J., Welin Henriksson E. Health-related quality of life, fatigue and mood in patients with SLE and high levels of pain compared to controls and patients with low levels of pain Lupus 2013;22 (11):1118-1127 [PubMed]
• Strand V., Galateanu C., Pushparajah D. S., Nikaï E., Sayers J., Wood R., van Vollenhoven R. F. Limitations of current treatments for systemic lupus erythematosus: a patient and physician survey Lupus 2013;22 (8):819-826 [PubMed]
• Jónsdóttir Thórunn, Zickert Agneta, Sundelin Birgitta, Henriksson Elisabet W., van Vollenhoven Ronald F., Gunnarsson Iva Long-term follow-up in lupus nephritis patients treated with rituximab-clinical and histopathological response Rheumatology (Oxford, England) 2013;52 (5):847-855 [PubMed]
• Genovese Mark C., Rubbert-Roth Andrea, Smolen Josef S., Kremer Joel, Khraishi Majed, Gómez-Reino Juan, Sebba Anthony, Pilson Robert, Williams Sarah, van Vollenhoven Ronald Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure Journal of rheumatology 2013;40 (6):768-780 [PubMed]
• van Vollenhoven Ronald F., Emery Paul, Bingham Clifton O., Keystone Edward C., Fleischmann Roy M., Furst Daniel E., Tyson Nicola, Collinson Neil, Lehane Patricia B. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients Annals of the rheumatic diseases 2013;72 (9):1496-1502 [PubMed]
• Mosca Marta, van Vollenhoven Ronald New drugs in systemic lupus erythematosus: when to start and when to stop Clinical and experimental rheumatology 2013;31 (4 78):S82-S85 [PubMed]
• Combe Bernard, van Vollenhoven Ronald Novel targeted therapies: the future of rheumatoid arthritis? Mavrilumab and tabalumab as examples Annals of the rheumatic diseases 2013;72 (9):1433-1435 [PubMed]
• Szepietowski Jacek C., Nilganuwong Surasak, Wozniacka Anna, Kuhn Annegret, Nyberg Filippa, van Vollenhoven Ronald F., Bengtsson Anders A., Reich Adam, de Vries Dick E., van Hartingsveldt Bart, Robinson Donald W., Gordon Robert, Hsu Benjamin Phase I, Randomized, Double-Blind, Placebo-Controlled, Multiple Intravenous, Dose-Ascending Study of Sirukumab in Cutaneous or Systemic Lupus Erythematosus Arthritis and rheumatism 2013;65 (10):2661-2671 [PubMed]
• van Vollenhoven Ronald F. Progress in RA genetics, pathology and therapy Nature reviews. Rheumatology 2013;9 (2):70-72 [PubMed]
• Raaschou Pauline, Simard Julia F., Holmqvist Marie, Askling Johan, Baecklund Eva, Coster Lars, Forsblad Helena, Feltelius Nils, Geboreck Pierre, Jacobsson Lennart, Klareskog Lars, Lindblad Staffan, Rantapaa-Dahlqvist Solbritt, Saxne Tore, van Vollenhoven Ronald Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden BMJ (Clinical research ed.) 2013;346:f1939 [PubMed]
• van Vollenhoven Ronald F., Chatzidionysiou Katerina RHEUMATOID ARTHRITIS Triple therapy or etanercept after methotrexate failure in RA? Nature reviews. Rheumatology 2013;9 (9):510-512 [PubMed]
• Chatzidionysiou K., van Vollenhoven R. F. Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort Scandinavian journal of rheumatology 2013;42 (3):190-195 [PubMed]
• Wallace D. J., Navarra S., Petri M. A., Gallacher A., Thomas M., Furie R., Levy R. A., van Vollenhoven R. F., Cooper S., Zhong Z. J., Freimuth W., Cervera R. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus Lupus 2013;22 (2):144-154 [PubMed]
• van Vollenhoven Ronald F. Small molecular compounds in development for rheumatoid arthritis Current opinion in rheumatology 2013;25 (3):391-397 [PubMed]
• Lekander Ingrid, Kobelt Gisela, Svarvar Patrick, Ljung Tryggve, van Vollenhoven Ronald, Borgström Fredrik The Comparison of Trial Data-Based and Registry Data-Based Cost-Effectiveness of Infliximab Treatment for Rheumatoid Arthritis in Sweden Using a Modeling Approach Value in health 2013;16 (2):251-258 [PubMed]
• Lekander Ingrid, Borgström Fredrik, Lysholm Jörgen, van Vollenhoven Ronald F., Lindblad Staffan, Geborek Pierre, Kobelt Gisela The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice European journal of health economics : HEPAC 2013;14 (6):863-873 [PubMed]
• Gabay Cem, Emery Paul, van Vollenhoven Ronald, Dikranian Ara, Alten Rieke, Pavelka Karel, Klearman Micki, Musselman David, Agarwal Sunil, Green Jennifer, Kavanaugh Arthur, Elizondo-Alanis Luis-Jamie, Zazueta Beatriz, Sherran Tom, Hakim Alan, Borofsky Michael, Chindalore Vishala, Lawson Jeffrey, Scoville Craig D., Logan James, Waller Phillip, Wolfe Sanford, Bushan Naga, Dikranian Ara H., Fung Eugene, Ettlinger Robert, Hensarling James K., King Charles M., Kivitiz Alan, Halter Dale, Kohen Michael D., Jerdan Dennis, Samuels Bruce S., Churchill Melvin, Payne Dennis, Kenney Howard, Hsu Vivien, Isaacs John, Sayers Michael, Rizzo Warren C., Singhal Atil K., Trapp Robert, Youssef Peter, Nash Peter, Dudler Jean, Malaise Michel, Kyburz Diego, Müller Rudiger, Thompson Paul W., Alvaro-Gracia Jose M. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial Lancet 2013;381 (9877):1541-1550 [PubMed]
• Gabay C., Emery P., van Vollenhoven R. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial (vol 381, pg 1541, 2013) Lancet 2013;381 (9877):1540
• Gabay C., Emery P., van Vollenhoven R. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial (vol 381, pg 1541, 2013) Lancet 2013;382 (9908):1878

2012

• Mullazehi Mohammed, Wick Marius C., Klareskog Lars, van Vollenhoven Ronald, Rönnelid Johan Anti-type II collagen antibodies are associated with early radiographic destruction in rheumatoid arthritis Arthritis research & therapy 2012;14 (3):R100 [PubMed]
• van Vollenhoven Ronald F., Petri Michelle A., Cervera Ricard, Roth David A., Ji Beulah N., Kleoudis Christi S., Zhong Z. John, Freimuth William Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response Annals of the rheumatic diseases 2012;71 (8):1343-1349 [PubMed]
• Nordström Dan, Knight Ann, Luukkainen Reijo, van Vollenhoven Ronald, Rantalaiho Vappu, Kajalainen Anna, Brun Johan G., Proven Anne, Ljung Lotta, Kautiainen Hannu, Pettersson Tom Beneficial Effect of Interleukin 1 Inhibition with Anakinra in Adult-onset Still's Disease. An Open, Randomized, Multicenter Study Journal of rheumatology 2012;39 (10):2008-2011 [PubMed]
• Gunnarsson Iva, van Vollenhoven Ronald F. Biologicals for the treatment of systemic lupus erythematosus? Annals of medicine 2012;44 (3):225-232 [PubMed]
• van Vollenhoven Ronald F., Geborek Pierre, Forslind Kristina, Albertsson Kristina, Ernestam Sofia, Petersson Ingemar F., Chatzidionysiou Katerina, Bratt Johan, Cöster Lars, Zickert Agneta, Theander Jan, Thörner Åke, Hellström Helena, Teleman Annika, Dackhammar Christina, Akre Finn, Ljung Lotta, Oding Rolf, Wörnert Margareta Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial Lancet 2012;379 (9827):1712-1720 [PubMed]
• Petri Michelle, Orbai Ana-Maria, Alarcón Graciela S., Gordon Caroline, Merrill Joan T., Fortin Paul R., Bruce Ian N., Isenberg David, Wallace Daniel J., Nived Ola, Sturfelt Gunnar, Ramsey-Goldman Rosalind, Bae Sang-Cheol, Hanly John G., Sánchez-Guerrero Jorge, Clarke Ann, Aranow Cynthia, Manzi Susan, Urowitz Murray, Gladman Dafna, Kalunian Kenneth, Costner Melissa, Werth Victoria P., Zoma Asad, Bernatsky Sasha, Ruiz-Irastorza Guillermo, Khamashta Munther A., Jacobsen Soren, Buyon Jill P., Maddison Peter, Dooley Mary Anne, van Vollenhoven Ronald F., Ginzler Ellen, Stoll Thomas, Peschken Christine, Jorizzo Joseph L., Callen Jeffrey P., Lim S. Sam, Fessler Barri J., Inanc Murat, Kamen Diane L., Rahman Anisur, Steinsson Kristjan, Franks Andrew G., Sigler Lisa, Hameed Suhail, Fang Hong, Pham Ngoc, Brey Robin, Weisman Michael H., McGwin Gerald, Magder Laurence S. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus Arthritis and rheumatism 2012;64 (8):2677-2686 [PubMed]
• Chatzidionysiou Katerina, Lie Elisabeth, Nasonov Evgeny, Lukina Galina, Hetland Merete Lund, Tarp Ulrik, van Riel Piet L. C. M., Nordström Dan C., Gomez-Reino Juan, Pavelka Karel, Tomsic Matija, Kvien Tore K., van Vollenhoven Ronald F., Gabay Cem Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration Annals of the rheumatic diseases 2012;71 (3):374-377 [PubMed]
• Weinblatt Michael E., Fleischmann Roy, Huizinga Tom W. J., Emery Paul, Pope Janet, Massarotti Elena M., van Vollenhoven Ronald F., Wollenhaupt Jürgen, Bingham Clifton O., Duncan Ben, Goel Niti, Davies Owen R., Dougados Maxime Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study Rheumatology (Oxford, England) 2012;51 (12):2204-2214 [PubMed]
• Urowitz M. B., Gladman D. D., Ibañez D., Fortin P. R., Bae S. C., Gordon C., Clarke A., Bernatsky S., Hanly J. G., Isenberg D., Rahman A., Sanchez-Guerrero J., Wallace D. J., Ginzler E., Alarcón G. S., Merrill J. T., Bruce I. N., Sturfelt G., Nived O., Steinsson K., Khamashta M., Petri M., Manzi S., Ramsey-Goldman R., Dooley M. A., van Vollenhoven R. F., Ramos M., Stoll T., Zoma A., Kalunian K., Aranow C. Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort Arthritis care & research 2012;64 (1):132-137 [PubMed]
• Lesuis Nienke, Befrits Ragnar, Nyberg Filippa, van Vollenhoven Ronald F. Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study BMC medicine 2012;10:82 [PubMed]
• Arkema Elizabeth V., van Vollenhoven Ronald F., Askling Johan, Baecklund E., Coster L., Forsblad-Elia C., Feltelius N., Geborek P., Jacobsson L., Klareskog L., Lindblad S., Rantapaa-Dahlqvist S., Saxne T. Incidence of progressive multifocal leukoencephalopathy in patients with rheumatoid arthritis: a national population-based study Annals of the rheumatic diseases 2012;71 (11):1865-1867 [PubMed]
• Rezaei Hamed, Saevarsdottir Saedis, Forslind Kristina, Albertsson Kristina, Wallin Helena, Bratt Johan, Ernestam Sofia, Geborek Pierre, Pettersson Ingemar F., van Vollenhoven Ronald F. In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial Annals of the rheumatic diseases 2012;71 (2):186-191 [PubMed]
• Kastbom Alf, Cöster Lars, Arlestig Lisbeth, Chatzidionysiou Aikaterini, van Vollenhoven Ronald F., Padyukov Leonid, Rantapää-Dahlqvist Solbritt, Saevarsdottir Saedis Influence of FCGR3A genotype on the therapeutic response to rituximab in rheumatoid arthritis: an observational cohort study BMJ open 2012;2 (5):e001524 [PubMed]
• Arkema Elizabeth V., Neovius Martin, Joelsson Joel K., Simard Julia F., van Vollenhoven Ronald F. Is there a sex bias in prescribing anti-tumour necrosis factor medications to patients with rheumatoid arthritis? A nation-wide cross-sectional study Annals of the rheumatic diseases 2012;71 (7):1203-1206 [PubMed]
• Bertsias George K., Tektonidou Maria, Amoura Zahir, Aringer Martin, Bajema Ingeborg, Berden Jo H. M., Boletis John, Cervera Ricard, Dörner Thomas, Doria Andrea, Ferrario Franco, Floege Jürgen, Houssiau Frederic A., Ioannidis John P. A., Isenberg David A., Kallenberg Cees G. M., Lightstone Liz, Marks Stephen D., Martini Alberto, Moroni Gabriela, Neumann Irmgard, Praga Manuel, Schneider Matthias, Starra Argyre, Tesar Vladimir, Vasconcelos Carlos, van Vollenhoven Ronald F., Zakharova Helena, Haubitz Marion, Gordon Caroline, Jayne David, Boumpas Dimitrios T. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis Annals of the rheumatic diseases 2012;71 (11):1771-1782 [PubMed]
• Simard Julia F., Neovius Martin, Askling Johan, Baecklund E., Cöster L., Forsbladd'Elia H., Feltelius N., Geborek P., Jacobsson L., Klareskog L., Lindblad S., Rantapää-Dahlqvist S., Saxne T., van Vollenhoven R. Mortality Rates in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors Drug-Specific Comparisons in the Swedish Biologics Register Arthritis and rheumatism 2012;64 (11):3502-3510 [PubMed]
• Dervieux Thierry, Wessels Judith A. M., Kremer Joel M., Padyukov Leonid, Seddighzadeh Maria, Saevarsdottir Saedis, van Vollenhoven Ronald F., Klareskog Lars, Huizinga Tom W., Guchelaar Henk-Jan Patterns of interaction between genetic and nongenetic attributes and methotrexate efficacy in rheumatoid arthritis Pharmacogenetics and genomics 2012;22 (1):1-9 [PubMed]
• Bengtsson Anders A., Sturfelt Gunnar, Lood Christian, Rönnblom Lars, van Vollenhoven Ronald F., Axelsson Bengt, Sparre Birgitta, Tuvesson Helén, Ohman Marie Wallén, Leanderson Tomas Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: Studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus Arthritis and rheumatism 2012;64 (5):1579-1588 [PubMed]
• Björkander S., Bremme K., Persson J.-O., van Vollenhoven R. F., Sverremark-Ekström E., Holmlund U. Pregnancy-associated inflammatory markers are elevated in pregnant women with systemic lupus erythematosus Cytokine 2012;59 (2):392-399 [PubMed]
• Rudin Anna, Sturfelt Gunnar, Carlsten Hans, Hafström Ingiäld, Lundberg Ingrid, Klareskog Lars, Rönnblom Lars, Jacobsson Lennart, van Vollenhoven Ronald, Rantapää-Dahlqvist Solbritt, Skogh Thomas, Saxne Tore Reumatologisk forskning med försöksdjur är viktig för våra patienter Lakartidningen 2012;109 (1-2):40 [PubMed]
• van Vollenhoven Ronald F. Rituximab - Shadow, illusion or light? Autoimmunity reviews 2012;11 (8):563-567 [PubMed]
• Hanly John G., Urowitz Murray B., Su Li, Gordon Caroline, Bae Sang-Cheol, Sanchez-Guerrero Jorge, Romero-Diaz Juanita, Wallace Daniel J., Clarke Ann E., Ginzler E. M., Merrill Joan T., Isenberg David A., Rahman Anisur, Petri M., Fortin Paul R., Gladman D. D., Bruce Ian N., Steinsson Kristjan, Dooley M. A., Khamashta Munther A., Alarcón Graciela S., Fessler Barri J., Ramsey-Goldman Rosalind, Manzi Susan, Zoma Asad A., Sturfelt Gunnar K., Nived Ola, Aranow Cynthia, Mackay Meggan, Ramos-Casals Manuel, van Vollenhoven R. F., Kalunian Kenneth C., Ruiz-Irastorza Guillermo, Lim Sam, Kamen Diane L., Peschken Christine A., Inanc Murat, Theriault Chris, Thompson Kara, Farewell Vernon Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study Annals of the rheumatic diseases 2012;71 (9):1502-1509 [PubMed]
• Keystone Edward C., Combe Bernard, Smolen Josef, Strand Vibeke, Goel Niti, van Vollenhoven Ronald, Mease Philip, Landewé Robert, Fleischmann Roy, Luijtens Kristel, van der Heijde Désirée Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial Rheumatology (Oxford, England) 2012;51 (9):1628-1638 [PubMed]
• Tak Paul P., Rigby William, Rubbert-Roth Andrea, Peterfy Charles, van Vollenhoven Ronald F., Stohl William, Healy Emma, Hessey Eva, Reynard Mark, Shaw Tim Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE Annals of the rheumatic diseases 2012;71 (3):351-357 [PubMed]
• van Vollenhoven Ronald F., Fleischmann Roy, Cohen Stanley, Lee Eun Bong, Garcia Meijide Juan A., Wagner Sylke, Forejtova Sarka, Zwillich Samuel H., Gruben David, Koncz Tamas, Wallenstein Gene V., Krishnaswami Sriram, Bradley John D., Wilkinson Bethanie, Bossingham David H., Hall Stephen, Nash Peter T., Schrieber Leslie, Sokolovic Sekib, Oparanov Boycho, Yablanski Kiril, Batalov Anastas, Bichovska Daniela, Goranov Ivan, Nikolov Nikolay G., Chow Andrew, Klinkhoff Alice V., Beaulieu Andre Damien, Pope Janet, Tremblay Jean-Luc, Nair Bindu, Wilson Diane B., Aliste Marta, Ballesteros Francisco, Holuigue Gloria, Flores Ana Maria, Alpizar Raul, Brenes-Silesky Francisco, Alfaro-Vargas Daniel, Kaliterna Dusanka Martinovic, Cikes Nada, Prus Visnja, Rosa Jan, Nemec Petr, Vitek Petr, Dvorak Zdenek, Novosad Libor, Urbanova Zuzana, Mosterova Zdenka, Danneskiold-Samsoe Bente Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis New England journal of medicine 2012;367 (6):508-519 [PubMed]
• Mosca Marta, Boumpas Dimitrios T., Bruce Ian N., Cervera Ricard, Czirjak Laszlo, Dörner Thomas, Houssiau Frédéric, Jacobsen Soren, Schneider Matthias, Smolen Josef S., Voskuyl Alexandre E., van Vollenhoven Ronald F. Treat-to-target in systemic lupus erythematosus: where are we today? Clinical and experimental rheumatology 2012;30 (4 Suppl 73):S112-S115 [PubMed]

2011

• van Vollenhoven R. F., Felson D., Strand V., Weinblatt M. E., Luijtens K., Keystone E. C. American College of Rheumatology Hybrid Analysis of Certolizumab Pegol Plus Methotrexate in Patients With Active Rheumatoid Arthritis: Data From a 52-Week Phase III Trial Arthritis care & research 2011;63 (1):128-134 [PubMed]
• Fisher Benjamin A., Plant Darren, Brode Monica, van Vollenhoven Ronald F., Mathsson Linda, Symmons Deborah, Lundberg Karin, Rönnelid Johan, Venables Patrick J. Antibodies to citrullinated alpha-enolase peptide 1 and clinical and radiological outcomes in rheumatoid arthritis Annals of the rheumatic diseases 2011;70 (6):1095-1098 [PubMed]
• Furie Richard, Petri Michelle, Zamani Omid, Cervera Ricard, Wallace Daniel J., Tegzová Dana, Sanchez-Guerrero Jorge, Schwarting Andreas, Merrill Joan T., Chatham W. Winn, Stohl William, Ginzler Ellen M., Hough Douglas R., Zhong Z. John, Freimuth William, van Vollenhoven Ronald F. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus Arthritis and rheumatism 2011;63 (12):3918-3930 [PubMed]
• van Vollenhoven R. F., Kinnman N., Vincent E., Wax S., Bathon J. Atacicept in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate Results of a Phase II, Randomized, Placebo-Controlled Trial Arthritis and rheumatism 2011;63 (7):1782-1792 [PubMed]
• Hanly J. G., Urowitz M. B., Su L., Bae S.-C., Gordon C., Clarke A., Bernatsky S., Vasudevan A., Isenberg D., Rahman A., Wallace D. J., Fortin P. R., Gladman D., Romero-Diaz J., Romero-Dirz J., Sanchez-Guerrero J., Dooley M. A., Bruce I., Steinsson K., Khamashta M., Manzi S., Ramsey-Goldman R., Sturfelt G., Nived O., van Vollenhoven R., Ramos-Casals M., Aranow C., Mackay M., Kalunian K., Alarcón G. S., Fessler B. J., Ruiz-Irastorza G., Petri M., Lim S., Kamen D., Peschken C., Farewell V., Thompson K., Theriault C., Merrill J. T. Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus Annals of the rheumatic diseases 2011;70 (10):1726-1732 [PubMed]
• Ippolito A., Wallace D. J., Gladman D., Fortin P. R., Urowitz M., Werth V., Costner M., Gordon C., Alarcón G. S., Ramsey-Goldman R., Maddison P., Clarke A., Bernatsky S., Manzi S., Bae S.-C., Merrill J. T., Ginzler E., Hanly J. G., Nived O., Sturfelt G., Sanchez-Guerrero J., Bruce I., Aranow C., Isenberg D., Zoma A., Magder L. S., Buyon J., Kalunian K., Dooley M. A., Steinsson K., van Vollenhoven R. F., Stoll T., Weisman M., Petri M. Autoantibodies in systemic lupus erythematosus: comparison of historical and current assessment of seropositivity Lupus 2011;20 (3):250-255 [PubMed]
• Strand Vibeke, Smolen Josef S., van Vollenhoven Ronald F., Mease Philip, Burmester Gerd R., Hiepe Falk, Khanna Dinesh, Nikaï Enkeleida, Coteur Geoffroy, Schiff Michael Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial Annals of the rheumatic diseases 2011;70 (6):996-1002 [PubMed]
• Vinet Evelyne, Clarke Ann E., Gordon Caroline, Urowitz Murray B., Hanly John G., Pineau Christian A., Isenberg David, Rahman Anisur, Wallace Daniel, Alarcón Graciela S., Bruce Ian, Petri Michelle, Dooley Mary Ann, Kalunian Kenneth, Maddison Peter, Aranow Cynthia, van Vollenhoven Ronald, Bernatsky Sasha Decreased Live Births in Women With Systemic Lupus Erythematosus Arthritis care & research 2011;63 (7):1068-1072 [PubMed]
• Raaschou Pauline, Simard Julia F., Neovius Martin, Askling Johan, Baecklund Eva, Cöster Lars Cöster, Dackhammar Christina, Feltelius Nils, Geborek Pierre, Jacobsson Lennart, Klareskog Lars, Lindblad Staffan, Rantapää-Dahlqvist Solbritt, Saxne Tore, van Vollenhoven Ronald Does Cancer That Occurs During or After Anti-Tumor Necrosis Factor Therapy Have a Worse Prognosis? A National Assessment of Overall and Site-Specific Cancer Survival in Rheumatoid Arthritis Patients Treated With Biologic Agents Arthritis and rheumatism 2011;63 (7):1812-1822 [PubMed]
• Chatzidionysiou Katerina, Lie Elisabeth, Nasonov Evgeny, Lukina Galina, Hetland Merete Lund, Tarp Ulrik, Gabay Cem, van Riel Piet L. C. M., Nordström Dan C., Gomez-Reino Juan, Pavelka Karel, Tomsic Matija, Kvien Tore K., van Vollenhoven Ronald F. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries Annals of the rheumatic diseases 2011;70 (9):1575-1580 [PubMed]
• Neovius Martin, Simard Julia F., Askling Johan, Baecklund E., Cöster L., Dackhammar C., Feltelius N., Geborek P., Jacobsson L., Klareskog L., Lindblad S., Rantapaa-Dahlqvist S., Saxne T., van Vollenhoven R. How large are the productivity losses in contemporary patients with RA, and how soon in relation to diagnosis do they develop? Annals of the rheumatic diseases 2011;70 (6):1010-1015 [PubMed]
• Tak P. P., Rigby W. F., Rubbert-Roth A., Peterfy C. G., van Vollenhoven R. F., Stohl W., Hessey E., Chen A., Tyrrell H., Shaw T. M. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial Annals of the rheumatic diseases 2011;70 (1):39-46 [PubMed]
• Schiff Michael H., Kremer Joel M., Jahreis Angelika, Vernon Emma, Isaacs John D., van Vollenhoven Ronald F. Integrated safety in tocilizumab clinical trials Arthritis research & therapy 2011;13 (5):R141 [PubMed]
• Ruperto N., Hanrahan L. M., Alarcón G. S., Belmont H. M., Brey R. L., Brunetta P., Buyon J. P., Costner M. I., Cronin M. E., Dooley M. A., Filocamo G., Fiorentino D., Fortin P. R., Franks A. G., Gilkeson G., Ginzler E., Gordon C., GROSSMAN J., Hahn B., Isenberg D. A., Kalunian K. C., Petri M., Sammaritano L., Sánchez-Guerrero J., Sontheimer R. D., Strand V., Urowitz M., von Feldt J. M., Werth V. P., Merrill J. T., Ahearn Joseph, Akil Mohammed, Amos Michael D., Anolik Jennifer, Appel Gerald, Aranow Cynthia, Avcin Tadej, Novotney Barry Anna, Bass Damon, Becker Jean-Claude, Behrens Timothy W., Beresford Michael W., Boackle Susan, Boumpas Dimitrios, Bruce Ian, Brunner Hermine, Burgos-Vargas Ruben, Chen Shunle, Chevrier Marc, van Vollenhoven Ronald International consensus for a definition of disease flare in lupus Lupus 2011;20 (5):453-462 [PubMed]
• van Vollenhoven Ronald F., Severens Johan L. Introduction Clinical rheumatology 2011;30 (1):S1-S2
• Mariette Xavier, Matucci-Cerinic Marco, Pavelka Karel, Taylor Peter, van Vollenhoven Ronald, Heatley Rebecca, Walsh Claire, Lawson Richard, Reynolds Alan, Emery Paul Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis Annals of the rheumatic diseases 2011;70 (11):1895-1904 [PubMed]
• van Vollenhoven Ronald F. More or Less Rituximab? Biology and Clinic, Regulators and Researchers Arthritis and rheumatism 2011;63 (3):594-596 [PubMed]
• Neovius Martin, Simard Julia F., Askling Johan, Baecklund E., Coster L., Dackhammar C., Feltelius N., Geborek P., Jacobsson L., Klareskog L., Lindblad S., Rantapaa-Dahlqvist S., Saxne T., van Vollenhoven R. Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden Annals of the rheumatic diseases 2011;70 (4):624-629 [PubMed]
• van Vollenhoven Ronald F., Severens Johan L. Observational studies: a valuable source for data on the true value of RA therapies Clinical rheumatology 2011;30 (1):S19-S24 [PubMed]
• Alemo Munters Li, van Vollenhoven Ronald F., Alexanderson Helene Patient preference assessment reveals disease aspects not covered by recommended outcomes in polymyositis and dermatomyositis ISRN rheumatology 2011;2011:463124 [PubMed]
• Saevarsdottir Saedis, Wallin Helena, Seddighzadeh Maria, Ernestam Sofia, Geborek Pierre, Petersson Ingemar F., Bratt Johan, van Vollenhoven Ronald F., Cöster Lars, Waltbrand Eva, Zickert Agneta, Theander Jan, Thörner Åke, Hellström Helena, Teleman Annika, Dackhammar Christina, Akre Finn, Forslind Kristina, Ljung Lotta, Oding Rolf, Chatzidionysiou Katerina, Wörnert Margareta Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial Annals of the rheumatic diseases 2011;70 (3):469-475 [PubMed]
• Jónsdóttir Thórunn, Sundelin Birgitta, Welin Henriksson Elisabet, van Vollenhoven Ronald F., Gunnarsson Iva Rituximab-treated membranous lupus nephritis: clinical outcome and effects on electron dense deposits Annals of the rheumatic diseases 2011;70 (6):1172-1173 [PubMed]
• Hanly J. G., Urowitz M. B., Jackson D., Bae S. C., Gordon C., Wallace D. J., Clarke A., Bernatsky S., Vasudevan A., Isenberg D., Rahman A., Sanchez-Guerrero J., Romero-Diaz J., Merrill J. T., Fortin P. R., Gladman D. D., Bruce I. N., Steinsson K., Khamashta M., Alarcón G. S., Fessler B., Petri M., Manzi S., Nived O., Sturfelt G., Ramsey-Goldman R., Dooley M. A., Aranow C., van Vollenhoven R., Ramos-Casals M., Zoma A., Kalunian K., Farewell V. SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus Annals of the rheumatic diseases 2011;70 (6):961-967 [PubMed]
• Neovius M., Simard J. F., Klareskog L., Askling J., Baecklund E., Cöster L., Dackhammar C., Feltelius N., Geborek P., Jacobsson L., Lindblad S., Rantapaa-Dahlqvist S., Saxne T., van Vollenhoven R. Sick leave and disability pension before and after initiation of antirheumatic therapies in clinical practice Annals of the rheumatic diseases 2011;70 (8):1407-1414 [PubMed]
• Neovius M., Sundström A., Simard Jf, Wettermark B., Cars T., Feltelius N., Askling J., Klareskog L., Baecklund E., Cöster L., Dackhammar C., Geborek P., Jacobsson L., Lindblad S., Rantapaa-Dahlqvist S., Saxne T., van Vollenhoven R. Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009 Scandinavian journal of rheumatology 2011;40 (1):8-15 [PubMed]
• Simard Julia F., Arkema Elizabeth V., Sundström Anders, Geborek Pierre, Saxne Tore, Baecklund Eva, Coster Lars, Dackhammar Christina, Jacobsson Lennart, Feltelius Nils, Lindblad Staffan, Rantapää-Dahlqvist Solbritt, Klareskog Lars, van Vollenhoven Ronald F., Neovius Martin, Askling Johan Ten years with biologics: to whom do data on effectiveness and safety apply? Rheumatology (Oxford, England) 2011;50 (1):204-213 [PubMed]
• van Vollenhoven Ronald F. Unresolved issues in biologic therapy for rheumatoid arthritis Nature reviews. Rheumatology 2011;7 (4):205-215 [PubMed]
• Buch Maya H., Smolen Josef S., Betteridge Neil, Breedveld Ferdinand C., Burmester Gerd, Dörner Thomas, Ferraccioli Gianfranco, Gottenberg Jacques-Eric, Isaacs John, Kvien Tore K., Mariette Xavier, Martin-Mola Emilio, Pavelka Karel, Tak Paul P., van der Heijde Desiree, van Vollenhoven Ronald F., Emery Paul Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis Annals of the rheumatic diseases 2011;70 (6):909-920 [PubMed]
• Chatzidionysiou K., van Vollenhoven R. F. When to initiate and discontinue biologic treatments for rheumatoid arthritis? Journal of internal medicine 2011;269 (6):614-625 [PubMed]

2010

• Urowitz M. B., Gladman D., Ibañez D., Bae S. C., Sanchez-Guerrero J., Gordon C., Clarke A., Bernatsky S., Fortin P. R., Hanly J. G., Wallace D. J., Isenberg D., Rahman A., Alarcón G. S., Merrill J. T., Ginzler E., Khamashta M., Nived O., Sturfelt G., Bruce I. N., Steinsson K., Manzi S., Ramsey-Goldman R., Dooley M. A., Zoma A., Kalunian K., Ramos M., van Vollenhoven R. F., Aranow C., Stoll T., Petri M., Maddison P. Atherosclerotic Vascular Events in a Multinational Inception Cohort of Systemic Lupus Erythematosus Arthritis care & research 2010;62 (6):881-887 [PubMed]
• Riazzoli Jenny Biologocal thearpies - treatment outcome in RA-patients : Quality of life, health economy and pharmacotherapy 2010. 58p. ISBN 9789174097733. [UvA Dissertations Online] Karolinska Institute, Stockholm: Rheumatology, Dep of medicine. (Supervisor: van Vollenhoven R.; Co-supervisors: Eksborg S., Klareskog L.)
• Jónsdóttir Thórunn, Gunnarsson Iva, Mourão Ana Filipa, Lu Tim Y., van Vollenhoven Ronald F., Isenberg David Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohorts Rheumatology (Oxford, England) 2010;49 (8):1502-1504 [PubMed]
• Lekander Ingrid, Borgström Fredrik, Svarvar Patrick, Ljung Tryggve, Carli Cheryl, van Vollenhoven Ronald F. Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden International journal of technology assessment in health care 2010;26 (1):54-61 [PubMed]
• Nam J. L., Winthrop K. L., van Vollenhoven R. F., Pavelka K., Valesini G., Hensor E. M. A., Worthy G., Landewé R., Smolen J. S., Emery P., Buch M. H. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA Annals of the rheumatic diseases 2010;69 (6):976-986 [PubMed]
• Nossent J., Kiss E., Rozman B., Pokorny G., Vlachoyiannopoulos P., Olesinska M., Marchesoni A., Mosca M., Påi S., Manger K., Schneider M., Nielsen H., van Vollenhoven R., Swaak T. Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus Lupus 2010;19 (8):949-956 [PubMed]
• van den Bosch F., Manger B., Goupille P., McHugh N., Rødevand E., Holck P., van Vollenhoven R. F., Leirisalo-Repo M., FitzGerald O., Kron M., Frank M., Kary S., Kupper H. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions Annals of the rheumatic diseases 2010;69 (2):394-399 [PubMed]
• Smolen Josef S., Landewé Robert, Breedveld Ferdinand C., Dougados Maxime, Emery Paul, Gaujoux-Viala Cecile, Gorter Simone, Knevel Rachel, Nam Jackie, Schoels Monika, Aletaha Daniel, Buch Maya, Gossec Laure, Huizinga Tom, Bijlsma Johannes W. J. W., Burmester Gerd, Combe Bernard, Cutolo Maurizio, Gabay Cem, Gomez-Reino Juan, Kouloumas Marios, Kvien Tore K., Martin-Mola Emilio, McInnes Iain, Pavelka Karel, van Riel Piet, Scholte Marieke, Scott David L., Sokka Tuulikki, Valesini Guido, van Vollenhoven Ronald, Winthrop Kevin L., Wong John, Zink Angela, van der Heijde Désirée EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs Annals of the rheumatic diseases 2010;69 (6):964-975 [PubMed]
• Bertsias G. K., Ioannidis J. P. A., Aringer M., Bollen E., Bombardieri S., Bruce I. N., Cervera R., Dalakas M., Doria A., Hanly J. G., Huizinga T. W. J., Isenberg D., Kallenberg C., Piette J. C., Schneider M., Scolding N., Smolen J., Stara A., Tassiulas I., Tektonidou M., Tincani A., van Buchem M. A., van Vollenhoven R., Ward M., Gordon C., Boumpas D. T. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs Annals of the rheumatic diseases 2010;69 (12):2074-2082 [PubMed]
• Mosca M., Tani C., Aringer M., Bombardieri S., Boumpas D., Brey R., Cervera R., Doria A., Jayne D., Khamashta M. A., Kuhn A., Gordon C., Petri M., Rekvig O. P., Schneider M., Sherer Y., Shoenfeld Y., Smolen J. S., Talarico R., Tincani A., van Vollenhoven R. F., Ward M. M., Werth V. P., Carmona L. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies Annals of the rheumatic diseases 2010;69 (7):1269-1274 [PubMed]
• van Vollenhoven Ronald F., Cifaldi Mary A., Ray Saurabh, Chen Naijun, Weisman Michael H. Improvement in Work Place and Household Productivity for Patients With Early Rheumatoid Arthritis Treated With Adalimumab Plus Methotrexate: Work Outcomes and Their Correlations With Clinical and Radiographic Measures From a Randomized Controlled Trial Companion Study Arthritis care & research 2010;62 (2):226-234 [PubMed]
• Emery P., Genovese M. C., van Vollenhoven R., Sharp J. T., Patra K., Sasso E. H. Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis (vol 36, pg 1429, 2009) Journal of rheumatology 2010;37 (5):1081
• Emery P., Genovese M. C., van Vollenhoven R., Sharp J. T., Patra K., Sasso E. H. Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. (vol 36, pg 1429, 2009) Journal of rheumatology 2010;37 (6):1367
• Emery P., Genovese M. C., van Vollenhoven R., Sharp J. T., Patra K., Sasso E. H. Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. (vol 36, pg 1429, 2009) Journal of rheumatology 2010;37 (10):2198
• van Vollenhoven Ronald F., Emery Paul, Bingham Clifton O., Keystone Edward C., Fleischmann Roy, Furst Daniel E., Macey Katherine, Sweetser Marianne, Kelman Ariella, Rao Ravi Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials Journal of rheumatology 2010;37 (3):558-567 [PubMed]
• van Vollenhoven R. F., Emery P., Bingham C. O. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials (vol 37, pg 558, 2010) Journal of rheumatology 2010;37 (10):2198
• van Vollenhoven Ronald F. New and Future Agents in the Treatment of Rheumatoid Arthritis Discovery medicine 2010;9 (47):319-327 [PubMed]
• Riazzoli Jenny, Nilsson Jan-Åke, Teleman Annika, Petersson Ingemar F., Rantapää-Dahlqvist Solbritt, Jacobsson Lennart T. H., van Vollenhoven Ronald F. Patient-reported 28 swollen and tender joint counts accurately represent RA disease activity and can be used to assess therapy responses at the group level Rheumatology (Oxford, England) 2010;49 (11):2098-2103 [PubMed]
• Augustsson J., Neovius M., Cullinane-Carli C., Eksborg S., van Vollenhoven R. F. Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data from a population-based registry) Annals of the rheumatic diseases 2010;69 (1):126-131 [PubMed]
• Hanly J. G., Urowitz M. B., Su L., Bae S. C., Gordon C., Wallace D. J., Clarke A., Bernatsky S., Isenberg D., Rahman A., Alarcón G. S., Gladman D. D., Fortin P. R., Sanchez-Guerrero J., Romero-Diaz J., Merrill J. T., Ginzler E., Bruce I. N., Steinsson K., Khamashta M., Petri M., Manzi S., Dooley M. A., Ramsey-Goldman R., van Vollenhoven R., Nived O., Sturfelt G., Aranow C., Kalunian K., Ramos-Casals M., Zoma A., Douglas J., Thompson K., Farewell V. Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus Annals of the rheumatic diseases 2010;69 (3):529-535 [PubMed]
• van Vollenhoven Ronald F., Houbiers Jos G. A., Buttgereit Frank, In 't Hout Joanna, Boers Maarten, Leij Susanne, Kvien Tore K., Dijkmans Ben A. C., Szczepański Leszek, Szombati Istvan, Sierakowski Stanislaw, Miltenburg André M. M. The Selective Estrogen Receptor alpha Agonist Org 37663 Induces Estrogenic Effects but Lacks Antirheumatic Activity Arthritis and rheumatism 2010;62 (2):351-358 [PubMed]

2009

• van Vollenhoven R. F., Ernestam S., Geborek P., Petersson I. F., Cöster L., Waltbrand E., Zickert A., Theander J., Thörner A., Hellström H., Teleman A., Dackhammar C., Akre F., Forslind K., Ljung L., Oding R., Chatzidionysiou A., Wörnert M., Bratt J. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial Lancet 2009;374 (9688):459-466 [PubMed]
• Askling J., Baecklund E., Granath F., Geborek P., Fored M., Backlin C., Bertilsson L., Cöster L., Jacobsson L. T., Lindblad S., Lysholm J., Rantapää-Dahlqvist S., Saxne T., van Vollenhoven R., Klareskog L., Feltelius N. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register Annals of the rheumatic diseases 2009;68 (5):648-653 [PubMed]
• Jónsdóttir Thórunn B-cell depleting in systemic lupus erythematosus 2009. 60p. ISBN 9789174095098. [UvA Dissertations Online] Karolinska Institute, Stockholm, Sweden: Rheumatology Unit, Department of Medicine. (Supervisor: van Vollenhoven R.; Co-supervisors: Gunnarsson I., Klareskog L.)
• Hueber Wolfgang, Tomooka Beren H., Batliwalla Franak, Li Wentian, Monach Paul A., Tibshirani Robert J., van Vollenhoven Ronald F., Lampa Jon, Saito Kazuyoshi, Tanaka Yoshiya, Genovese Mark C., Klareskog Lars, Gregersen Peter K., Robinson William H. Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis Arthritis research & therapy 2009;11 (3):R76 [PubMed]
• Askling Johan, van Vollenhoven Ronald F., Granath Fredrik, Raaschou Pauline, Fored C. Michael, Baecklund Eva, Dackhammar Christina, Feltelius Nils, Cöster Lars, Geborek Pierre, Jacobsson Lennart T., Lindblad Staffan, Rantapää-Dahlqvist Solbritt, Saxne Tore, Klareskog Lars Cancer Risk in Patients With Rheumatoid Arthritis Treated With Anti-Tumor Necrosis Factor alpha Therapies Does the Risk Change With the Time Since Start of Treatment? Arthritis and rheumatism 2009;60 (11):3180-3189 [PubMed]
• Kavanaugh Arthur, Smolen Josef S., Emery Paul, Purcaru Oana, Keystone Edward, Richard Lance, Strand Vibeke, van Vollenhoven Ronald F. Effect of Certolizumab Pegol With Methotrexate on Home and Work Place Productivity and Social Activities in Patients With Active Rheumatoid Arthritis Arthritis and rheumatism 2009;61 (11):1592-1600 [PubMed]
• Fleischmann R., Vencovsky J., van Vollenhoven R. F., Borenstein D., Box J., Coteur G., Goel N., Brezinschek H.-P., Innes A., Strand V. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study Annals of the rheumatic diseases 2009;68 (6):805-811 [PubMed]
• Smolen J., Landewé R. B., Mease P., Brzezicki J., Mason D., Luijtens K., van Vollenhoven R. F., Kavanaugh A., Schiff M., Burmester G. R., Strand V., Vencovsky J., van der Heijde D. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial Annals of the rheumatic diseases 2009;68 (6):797-804 [PubMed]
• Gordon C., Bertsias G., Ioannidis J. P. A., Boletis J., Bombardieri S., Cervera R., Dostál C., Font J., Gilboe I.-M., Houssiau F., Huizinga T. W. J., Isenberg D., Kallenberg C. G. M., Khamashta M. A., Piette J.-C., Schneider M., Smolen J. S., Sturfelt G., Tincani A., van Vollenhoven R., Boumpas D. T. EULAR points to consider for conducting clinical trials in systemic lupus erythematosus Annals of the rheumatic diseases 2009;68 (4):470-476 [PubMed]
• Bertsias G. K., Ioannidis J. P. A., Boletis J., Bombardieri S., Cervera R., Dostal C., Font J., Gilboe I. M., Houssiau F., Huizinga T., Isenberg D., Kallenberg C. G. M., Khamashta M., Piette J. C., Schneider M., Smolen J., Sturfelt G., Tincani A., van Vollenhoven R., Boumpas D. T., Gordon C. EULAR points to consider for conducting clinical trials in systemic lupus erythematosus: literature based evidence for the selection of endpoints Annals of the rheumatic diseases 2009;68 (4):477-483 [PubMed]
• Emery P., van Vollenhoven R., Ostergaard M., Choy E., Combe B., Graninger W., Krueger K., Matucci-Cerinic M., Navarro F., van Riel P., Settas L., Steinfeld S. Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe Annals of the rheumatic diseases 2009;68 (4):456-459 [PubMed]
• van Vollenhoven Ronald F. How to dose infliximab in rheumatoid arthritis: new data on a serious issue Annals of the rheumatic diseases 2009;68 (8):1237-1239 [PubMed]
• Emery P., Keystone E., Tony H. P., Cantagrel A., van Vollenhoven R., Sanchez A. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. (vol 67, pg 1516, 2008) Annals of the rheumatic diseases 2009;68 (2):296
• Emery Paul, Genovese Mark C., van Vollenhoven Ronald, Sharp John T., Patra Kaushik, Sasso Eric H. Less Radiographic Progression with Adalimumab Plus Methotrexate Versus Methotrexate Monotherapy Across the Spectrum of Clinical Response in Early Rheumatoid Arthritis Journal of rheumatology 2009;36 (7):1429-1441 [PubMed]
• Lu T. Y.-T., Jonsdottir T., van Vollenhoven R. F. Prolonged B-cell depletion following rituximab therapy in systemic lupus erythematosus: a report of two cases. (vol 67, pg 1493, 2008) Annals of the rheumatic diseases 2009;68 (5):764
• Strand Vibeke, Mease Philip, Burmester Gerd R., Nikaï Enkeleida, Coteur Geoffroy, van Vollenhoven Ronald, Combe Bernard, Keystone Edward C., Kavanaugh Arthur Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial Arthritis research & therapy 2009;11 (6):R170 [PubMed]
• van Vollenhoven Ronald F. Sex differences in rheumatoid arthritis: more than meets the eye .. BMC medicine 2009;7:12 [PubMed]
• van Vollenhoven Ronald F. Treatment of rheumatoid arthritis: state of the art 2009 Nature reviews. Rheumatology 2009;5 (10):531-541 [PubMed]

2008

• Cardiel Mario H., Tumlin James A., Furie Richard A., Wallace Daniel J., Joh Tenshang, Linnik Matthew D., Abeles Micha, Aelion Jacob, Appel Gerald B., Aranow Cynthia, Ballou Stanley, Becker Michael A., Belmont H. Michael, Boling Eugene P., Bombardieri Stefano, Brodeur James, Buyon Jill, Condemi John J., Cronin Mary E., Cush John J., DeHoratius Raphael, Desir Deborah, Donohue John, Edwards Michael, El-Shahawy Mohamed A., Emery Paul, Ensworth Stephanie, Espinoza Luis R., Fondal Maria, Fortin Paul, Geppert Thomas, Gilkeson Gary S., Ginzler Ellen, Gorevic Peter, Granda Jose, Grossman Jennifer, Hiepe Falk, Howard Paul, Hura Claudia E., Jaffer Adrian, Jakes James, Kalden Joachim R., Kammer Gary M., Kaplan Mariana J., Kaplan Stanley, Katz Robert, Kennedy Alastair, Kenney Howard M., Khamashta Munther, van Vollenhoven Ronald Abetimus sodium for renal flare in systemic lupus erythematosus Arthritis and rheumatism 2008;58 (8):2470-2480 [PubMed]
• Urowitz M. B., Gladman D., Ibañez D., Fortin P., Sanchez-Guerrero J., Bae S., Clarke A., Bernatsky S., Gordon C., Hanly J., Wallace D., Isenberg D., Ginzler E., Merrill J., Alarcón G. S., Steinsson K., Petri M., Dooley M. A., Bruce I., Manzi S., Khamashta M., Ramsey-Goldman R., Zoma A., Sturfelt G., Nived O., Maddison P., Font J., van Vollenhoven R., Aranow C., Kalunian K., Stoll T. Accumulation of coronary artery disease risk factors actors over three years: Data from an international inception cohort Arthritis and rheumatism 2008;59 (2):176-180 [PubMed]
• Mathsson Linda, Mullazehi Mohammed, Wick Marius C., Sjöberg Olof, van Vollenhoven Ronald, Klareskog Lars, Rönnelid Johan Antibodies against citrullinated vimentin in rheumatoid arthritis Arthritis and rheumatism 2008;58 (1):36-45 [PubMed]
• Hanly J. G., Urowitz M. B., Siannis F., Farewell V., Gordon C., Bae S. C., Isenberg D., Dooley M. A., Clarke A., Bernatsky S., Gladman D., Fortin P. R., Manzi S., Steinsson K., Bruce I. N., Ginzler E., Aranow C., Wallace D. J., Ramsey-Goldman R., van Vollenhoven R., Sturfelt G., Nived O., Sanchez-Guerrero J., Alarcón G. S., Petri M., Khamashta M., Zoma A., Font J., Kalunian K., Douglas J., Qi Q., Thompson K., Merrill J. T. Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis Arthritis and rheumatism 2008;58 (3):843-853 [PubMed]
• Gunnarsson Iva, Jonsdottir Thorunn, van Vollenhoven Ronald F. CD20 epitope masking by rituximab: comment on the article by Gunnarsson et al - Reply Arthritis and rheumatism 2008;58 (2):634
• Keystone Edward, van der Heijde Désirée, Mason David, Landewé Robert, van Vollenhoven Ronald, Combe Bernard, Emery Paul, Strand Vibeke, Mease Philip, Desai Chintu, Pavelka Karel Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study Arthritis and rheumatism 2008;58 (11):3319-3329 [PubMed]
• Emery P., McInnes I. B., van Vollenhoven R., Kraan M. C. Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis Rheumatology (Oxford, England) 2008;47 (4):392-398 [PubMed]
• van Vollenhoven R. F. Comment on: Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry Rheumatology (Oxford, England) 2008;47 (7):1106-1107 [PubMed]
• Bertsias G., Ioannidis J. P. A., Boletis J., Bombardieri S., Cervera R., Dostal C., Font J., Gilboe I. M., Houssiau F., Huizinga T., Isenberg D., Kallenberg C. G. M., Khamashta M., Piette J. C., Schneider M., Smolen J., Sturfelt G., Tincani A., van Vollenhoven R., Gordon C., Boumpas D. T. EULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics Annals of the rheumatic diseases 2008;67 (2):195-205 [PubMed]
• Emery P., Keystone E., Tony H. P., Cantagrel A., van Vollenhoven R., Sanchez A., Alecock E., Lee J., Kremer J. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial Annals of the rheumatic diseases 2008;67 (11):1516-1523 [PubMed]
• van der Heijde D., Landewé R., van Vollenhoven R., Fatenejad S., Klareskog L. Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial Annals of the rheumatic diseases 2008;67 (9):1267-1270 [PubMed]
• Karonitsch T., Aletaha D., Boers M., Bombardieri S., Combe B., Dougados M., Emery P., Felson D., Gomez-Reino J., Keystone E., Kvien T. K., Martin-Mola E., Matucci-Cerinic M., Richards P., van Riel P., Siegel J., Smolen J. S., Sokka T., van der Heijde D., van Vollenhoven R., Ward M., Wells G., Zink A., Landewe R. Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients with rheumatoid arthritis Annals of the rheumatic diseases 2008;67 (10):1365-1373 [PubMed]
• Lu T. Y.-T., Jónsdóttir T., Jonsdottir T., van Vollenhoven R. F., Isenberg D. A. Prolonged B-cell depletion following rituximab therapy in systemic lupus erythematosus: a report of two cases Annals of the rheumatic diseases 2008;67 (10):1493-1494 [PubMed]
• Aletaha D., Landewe R., Karonitsch T., Bathon J., Boers M., Bombardier C., Bombardieri S., Choi H., Combe B., Dougados M., Emery P., Gomez-Reino J., Keystone E., Koch G., Kvien T. K., Martin-Mola E., Matucci-Cerinic M., Michaud K., O'Dell J., Paulus H., Pincus T., Richards P., Simon L., Siegel J., Smolen J. S., Sokka T., Strand V., Tugwell P., van der Heijde D., van Riel P., Vlad S., van Vollenhoven R., Ward M., Weinblatt M., Wells G., White B., Wolfe F., Zhang B., Zink A., Felson D. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations Annals of the rheumatic diseases 2008;67 (10):1360-1364 [PubMed]
• Aletaha D., Landewe R., Karonitsch T., Bathon J., Boers M., Bombardier C., Bombardieri S., Choi H., Combe B., Dougados M., Emery P., Gomez-Reino J., Keystone E., Koch G., Kvien T. K., Martin-Mola E., Matucci-Cerinic M., Michaud K., O'Dell J., Paulus H., Pincus T., Richards P., Simon L., Siegel J., Smolen J. S., Sokka T., Strand V., Tugwell P., van der Heijde D., van Riel P., Vlad S., van Vollenhoven R., Ward M., Weinblatt M., Wells G., White B., Wolfe F., Zhang B., Zink A., Felson D. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations Arthritis and rheumatism 2008;59 (10):1371-1377 [PubMed]
• van Vollenhoven Ronald F. Rheumatologists, take heart! We may be doing something right Arthritis research & therapy 2008;10 (2):105 [PubMed]
• Hanly J. G., Urowitz M. B., Su L., Sanchez-Guerrero J., Bae S. C., Gordon C., Wallace D. J., Isenberg D., Alarcón G. S., Merrill J. T., Clarke A., Bernatsky S., Dooley M. A., Fortin P. R., Gladman D., Steinsson K., Petri M., Bruce I. N., Manzi S., Khamashta M., Zoma A., Font J., van Vollenhoven R., Aranow C., Ginzler E., Nived O., Sturfelt G., Ramsey-Goldman R., Kalunian K., Douglas J., Qiufen Qi K., Thompson K., Farewell V. Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study Arthritis and rheumatism 2008;59 (5):721-729 [PubMed]
• Petri Michelle, Kasitanon Nuntana, Singh Sukminder, Link Kimberly, Magder Laurence, Bae Sang-Cheol, Hanly John G., Nived Ola, Sturfelt Gunnar, van Vollenhoven Ronald, Wallace Daniel J., Alarcón Graciela S., Adu Dwomoa, Avila-Casado Carmen, Bernatsky Sasha R., Bruce Ian N., Clarke Ann E., Contreras Gabriel, Fine Derek M., Gladman Dafna D., Gordon Caroline, Kalunian Kenneth C., Madaio Michael P., Rovin Brad H., Sanchez-Guerrero Jorge, Steinsson Kristjan, Aranow Cynthia, Balow James E., Buyon Jill P., Ginzler Ellen M., Khamashta Munther A., Urowitz Murray B., Dooley Mary Anne, Merrill Joan T., Ramsey-Goldman Rosalind, Font Josef, Tumlin James, Stoll Thomas, Zoma Asad Systemic lupus international collaborating clinics renal activity/response exercise - Comparison of agreement in rating renal response Arthritis and rheumatism 2008;58 (6):1789-1795 [PubMed]
• Petri Michelle, Kasitanon Nuntana, Lee Shin-Seok, Link Kimberly, Magder Laurence, Bae Sang-Cheol, Hanly John G., Isenberg David A., Nived Ola, Sturfelt Gunnar, van Vollenhoven Ronald, Wallace Daniel J., Alarcón Graciela S., Adu Dwomoa, Avila-Casado Carmen, Bernatsky Sasha R., Bruce Ian N., Clarke Ann E., Contreras Gabriel, Fine Derek M., Gladman Dafna D., Gordon Caroline, Kalunian Kenneth C., Madaio Michael P., Rovin Brad H., Sanchez-Guerrero Jorge, Steinsson Kristjan, Aranow Cynthia, Balow James E., Buyon Jill P., Ginzler Ellen M., Khamashta Munther A., Urowitz Murray B., Dooley Mary Anne, Merrill Joan T., Ramsey-Goldman Rosalind, Font Josef, Tumlin James, Stoll Thomas, Zoma Asad Systemic lupus international collaborating clinics renal activity/response exercise - Development of a renal activity score and renal response index Arthritis and rheumatism 2008;58 (6):1784-1788 [PubMed]
• van Vollenhoven R. F. The Janus of lupus - benefits and risks with B-cell therapy Lupus 2008;17 (5):447-449 [PubMed]
• Jónsdóttir T., Gunnarsson I., Risselada A., Henriksson E. W., Klareskog L., van Vollenhoven R. F. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response Annals of the rheumatic diseases 2008;67 (3):330-334 [PubMed]

2007

• Urowitz M. B., Gladman D., Ibañez D., Fortin P., Sanchez-Guerrero J., Bae S., Clarke A., Bernatsky S., Gordon C., Hanly J., Wallace D., Isenberg D., Ginzler E., Merrill J., Alarcon G., Steinsson K., Petri M., Dooley M. A., Bruce I., Manzi S., Khamashta M., Ramsey-Goldman R., Zoma A., Sturfelt G., Nived O., Maddison P., Font J., van Vollenhoven R., Aranow C., Kalunian K., Stoll T., Buyon J. Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort Lupus 2007;16 (9):731-735 [PubMed]
• Gunnarsson Iva, Sundelin Birgitta, Jónsdóttir Thorunn, Jacobson Stefan H., Henriksson Elisabet Welin, van Vollenhoven Ronald F. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis Arthritis and rheumatism 2007;56 (4):1263-1272 [PubMed]
• van Vollenhoven R. F., Klareskog L. Infliximab dosage and infusion frequency in clinical practice: experiences in the Stockholm biologics registry STURE Scandinavian journal of rheumatology 2007;36 (6):418-423 [PubMed]
• Augustsson Jenny, Eksborg Staffan, Ernestam Sofia, Gullström Eleanor, van Vollenhoven Ronald Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis Annals of the rheumatic diseases 2007;66 (11):1462-1466 [PubMed]
• Hanly J. G., Urowitz M. B., Sanchez-Guerrero J., Bae S. C., Gordon C., Wallace D. J., Isenberg D., Alarcón G. S., Clarke A., Bernatsky S., Merrill J. T., Petri M., Dooley M. A., Gladman D., Fortin P. R., Steinsson K., Bruce I., Manzi S., Khamashta M., Zoma A., Aranow C., Ginzler E., van Vollenhoven R., Font J., Sturfelt G., Nived O., Ramsey-Goldman R., Kalunian K., Douglas J., Thompson K., Farewell V. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus - An international inception cohort study Arthritis and rheumatism 2007;56 (1):265-273 [PubMed]
• Keystone Edward, Fleischmann Roy, Emery Paul, Furst Daniel E., van Vollenhoven Ronald, Bathon Joan, Dougados Maxime, Baldassare Andrew, Ferraccioli Gianfranco, Chubick Andrew, Udell James, Cravets Matthew W., Agarwal Sunil, Cooper Simon, Magrini Fabio Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis Arthritis and rheumatism 2007;56 (12):3896-3908 [PubMed]
• Fasth Andreas E. R., Snir Omri, Johansson Anna A. T., Nordmark Birgitta, Rahbar Afsar, Af Klint Erik, Björkström Niklas K., Ulfgren Ann-Kristin, van Vollenhoven Ronald F., Malmström Vivianne, Trollmo Christina Skewed distribution of proinflammatory CD4(+)CD28(null) T cells in rheumatoid arthritis Arthritis research & therapy 2007;9 (5):R87 [PubMed]
• van Vollenhoven Ronald F. Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue Annals of the rheumatic diseases 2007;66 (7):849-851 [PubMed]
• Askling Johan, Fored C. Michael, Brandt Lena, Baecklund Eva, Bertilsson Lennart, Feltelius Nils, Cöster Lars, Geborek Pierre, Jacobsson Lennart T., Lindblad Staffan, Lysholm Jörgen, Rantapää-Dahlqvist Solbritt, Saxne Tore, van Vollenhoven Ronald F., Klareskog Lars Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists Annals of the rheumatic diseases 2007;66 (10):1339-1344 [PubMed]
• Vallerskog Therese, Gunnarsson Iva, Widhe Mona, Risselada Anke, Klareskog Lars, van Vollenhoven Ronald, Malmström Vivianne, Trollmo Christina Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE Clinical immunology (Orlando, Fla.) 2007;122 (1):62-74 [PubMed]

2006

• Landewé Robert, van der Heijde Désirée, Klareskog Lars, van Vollenhoven Ronald, Fatenejad Saeed Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes Arthritis and rheumatism 2006;54 (10):3119-3125 [PubMed]
• Jacobson Stefan H., van Vollenhoven Ronald, Gunnarsson Iva Rituximab-induced long-term remission of membranous lupus nephritis Nephrology, dialysis, transplantation 2006;21 (6):1742-1743 [PubMed]
• Askling J., Fored C. M., Geborek P., Jacobsson L. T. H., van Vollenhoven R., Feltelius N., Lindblad S., Klareskog L. Swedish registers to examine drug safety and clinical issues in RA Annals of the rheumatic diseases 2006;65 (6):707-712 [PubMed]
• Emery Paul, Fleischmann Roy, Filipowicz-Sosnowska Anna, Schechtman Joy, Szczepanski Leszek, Kavanaugh Arthur, Racewicz Artur J., van Vollenhoven Ronald F., Li Nicole F., Agarwal Sunil, Hessey Eva W., Shaw Timothy M. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment - Results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial Arthritis and rheumatism 2006;54 (5):1390-1400 [PubMed]
• Breedveld Ferdinand C., Weisman Michael H., Kavanaugh Arthur F., Cohen Stanley B., Pavelka Karel, van Vollenhoven Ronald, Sharp John, Perez John L., Spencer-Green George T. The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment Arthritis and rheumatism 2006;54 (1):26-37 [PubMed]
• Pincus Theodore, Yazici Yusuf, van Vollenhoven Ronald Why are only 50% of courses of anti-tumor necrosis factor agents continued for only 2 years in some settings? Need for longterm observations in standard care to complement clinical trials Journal of rheumatology 2006;33 (12):2372-2375 [PubMed]

2005

• Wick M. C., Ernestam S., Lindblad S., Bratt J., Klareskog L., van Vollenhoven R. F. Adalimumab (Humira (R)) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade (R)) or etanercept (Enbrel (R)): results from the STURE registry at Karolinska University Hospital Scandinavian journal of rheumatology 2005;34 (5):353-358 [PubMed]
• van Vollenhoven Ronald Dehydroepiandrosterone versus placebo for Sjogren's syndrome: comment on the article by Pillemer et al Arthritis and rheumatism 2005;53 (4):626 [PubMed]
• Wick M. C., Lindblad S., Weiss R. J., Klareskog L., van Vollenhoven R. F. Estimated prediagnosis radiological progression: an important tool for studying the effects of early disease modifying antirheumatic drug treatment in rheumatoid arthritis Annals of the rheumatic diseases 2005;64 (1):134-137 [PubMed]
• van Vollenhoven R. F., Gullström E., Klareskog L. Feasibility of 1 hour infliximab infusions Annals of the rheumatic diseases 2005;64 (4):654 [PubMed]
• van Vollenhoven Ronald, Gunnarsson Iva In lupus nephritis, the benefit of rituximab monotherapy, as opposed to rituximab plus cyclophosphamide combination therapy, remains uncertain: comment on the article by Sfikakis et al Arthritis and rheumatism 2005;52 (12):4050-4051 [PubMed]
• Rönnelid J., Wick M. C., Lampa J., Lindblad S., Nordmark B., Klareskog L., van Vollenhoven R. F. Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression Annals of the rheumatic diseases 2005;64 (12):1744-1749 [PubMed]
• van Vollenhoven R. F., Askling J. Rheumatoid arthritis registries in Sweden Clinical and experimental rheumatology 2005;23 (5 39):S195-S200 [PubMed]
• van Vollenhoven Ronald F., Klareskog Lars The treatment of rheumatoid arthritis: Getting better all the time? Arthritis and rheumatism 2005;52 (4):991-994 [PubMed]

2004

• Bhat Neelima M., Bieber Marcia M., Yang Yuh-Cheng, Leu Yi-Shing, van Vollenhoven Ronald F., Teng Nelson N. H. B cell lymphoproliferative disorders and VH4-34 gene encoded antibodies Human antibodies 2004;13 (3):63-68 [PubMed]
• Kavanaugh A., van Vollenhoven R. F., Pincus T. Benefit/risk of new drugs for rheumatoid arthritis - Introduction Clinical and experimental rheumatology 2004;22 (5 35):S1
• van Vollenhoven R. F. Benefits and risks of biological agents: Lymphomas Clinical and experimental rheumatology 2004;22 (5 35):S122-S125 [PubMed]
• van Vollenhoven R. F., Gunnarsson I., Welin-Henriksson E., Sundelin B., Osterborg A., Jacobson S. H., Klareskog L. Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone Scandinavian journal of rheumatology 2004;33 (6):423-427 [PubMed]
• Cao Duojia, van Vollenhoven Ronald, Klareskog Lars, Trollmo Christina, Malmström Vivianne CD25(bright)CD4(+) regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease Arthritis research & therapy 2004;6 (4):R335-R346 [PubMed]
• Fasth A. E. R., Cao D., van Vollenhoven R., Trollmo C., Malmström V. CD28(null)CD4(+) T cells - Characterization of an effector memory T-cell population in patients with rheumatoid arthritis Scandinavian journal of immunology 2004;60 (1-2):199-208 [PubMed]
• Wick M. C., Lindblad S., Weiss R. J., Klareskog L., van Vollenhoven R. F. Clinical and radiological disease-course in a Swedish DMARD-treated early RA-inception cohort: an observational study Scandinavian journal of rheumatology 2004;33 (6):380-384 [PubMed]
• van Vollenhoven R. F. Do etanercept-naive patients with rheumatoid arthritis respond better to infliximab than patients for whom etanercept has failed? Reply Annals of the rheumatic diseases 2004;63 (5):608
• van Vollenhoven R. F., Brannemark S., Klareskog L. Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect Annals of the rheumatic diseases 2004;63 (4):426-430 [PubMed]
• Petri Michelle A., Mease Philip J., Merrill Joan T., Lahita Robert G., Iannini Mark J., Yocum David E., Ginzler Ellen M., Katz Robert S., Gluck Oscar S., Genovese Mark C., van Vollenhoven Ronald, Kalunian Kenneth C., Manzi Susan, Greenwald Maria W., Buyon Jill P., Olsen Nancy J., Schiff Michael H., Kavanaugh Arthur F., Caldwell Jacques R., Ramsey-Goldman Rosalind, St Clair E. William, Goldman Allan L., Egan Rita M., Polisson Richard P., Moder Kevin G., Rothfield Naomi F., Spencer Robert T., Hobbs Kathryn, Fessler Barri J., Calabrese Leonard H., Moreland Larry W., Cohen Stanley B., Quarles Betty J., Strand Vibeke, Gurwith Marc, Schwartz Kenneth E. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus - Results of a multicenter randomized, double-blind, placebo-controlled trial Arthritis and rheumatism 2004;50 (9):2858-2868 [PubMed]
• Wick M. C., Lindblad S., Klareskog L., van Vollenhoven R. F. Relationship between inflammation and joint destruction in early rheumatoid arthritis: a mathematical description Annals of the rheumatic diseases 2004;63 (7):848-852 [PubMed]
• van Vollenhoven R. F. Switching between biological agents Clinical and experimental rheumatology 2004;22 (5 35):S115-S121 [PubMed]
• Jonsdottir T., Forslid J., van Vollenhoven A., Harju A., Brannemark S., Klareskog L., van Vollenhoven R. F. Treatment with tumour necrosis factor a antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies Annals of the rheumatic diseases 2004;63 (9):1075-1078 [PubMed]

2003

• Kavanaugh Arthur, Genovese Mark, Baughman Jan, Kivitz Alan, Bulpitt Ken, Olsen Nancy, Weisman Michael, Matteson Eric, Furst Daniel, van Vollenhoven Ronald, Anderson James, Cohen Stanley, Wei Nathan, Meijerink Jan, Jacobs Cindy, Mocci Simonetta Allele and antigen-specific treatment of rheumatoid arthritis: A double blind, placebo controlled phase 1 trial Journal of rheumatology 2003;30 (3):449-454 [PubMed]
• van Vollenhoven Ronald F., Klareskog Lars Clinical responses to tumor necrosis factor alpha antagonists do not show a bimodal distribution - Data from the Stockholm tumor necrosis factor alpha followup registry Arthritis and rheumatism 2003;48 (6):1500-1503 [PubMed]
• van Vollenhoven Ronald F., Ernestam Sofia, Harju Anders, Bratt Johan, Klareskog Lars Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious Arthritis research & therapy 2003;5 (6):R347-R351 [PubMed]
• van Vollenhoven R., Harju A., Brannemark S., Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense Annals of the rheumatic diseases 2003;62 (12):1195-1198 [PubMed]

2002

• van Vollenhoven Ronald F. Dehydroepiandrosterone for the treatment of systemic lupus erythematosus Expert opinion on pharmacotherapy 2002;3 (1):23-31 [PubMed]
• Petri Michelle A., Lahita Robert G., van Vollenhoven Ronald F., Merrill Joan T., Schiff Michael, Ginzler Ellen M., Strand Vibeke, Kunz Arlene, Gorelick Kenneth J., Schwartz Kenneth E. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus - A double-blind, randomized, placebo-controlled trial Arthritis and rheumatism 2002;46 (7):1820-1829 [PubMed]
• Gunnarsson Iva, Sundelin Birgitta, Heimbürger Mikael, Forslid Jan, van Vollenhoven Ronald, Lundberg Ingrid, Jacobson Stefan H. Repeated renal biopsy in proliferative lupus nephritis - Predictive role of serum C1q and albuminuria Journal of rheumatology 2002;29 (4):693-699 [PubMed]
• Bhat Neelima M., Lee Lisa M., van Vollenhoven Ronald F., Teng Nelson N. H., Bieber Marcia M. VH4-34 encoded antibody in systemic lupus erythematosus: Effect of Isotype Journal of rheumatology 2002;29 (10):2114-2121 [PubMed]

2001

• Larsson P., Bratt J., Harju A., van Vollenhoven R., Klareskog L. Blockad av TNF alpha--ny behandlingsprincip vid svår reumatoid artrit Lakartidningen 2001;98 (8):828-831 [PubMed]
• Svenungsson E., Andersson M., Brundin L., van Vollenhoven R., Khademi M., Tarkowski A., Greitz D., Dahlström M., Lundberg I., Klareskog L., Olsson T. Increased levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus erythematosus Annals of the rheumatic diseases 2001;60 (4):372-379 [PubMed]
• Berg L., Lampa J., Rogberg S., van Vollenhoven R., Klareskog L. Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNF alpha receptors Annals of the rheumatic diseases 2001;60 (2):133-139 [PubMed]

2000

• van Vollenhoven R. F. Dehydroepiandrosterone in the treatment of systemic lupus erythematosus Rheumatology (Oxford, England) 2000;39 (8):929-930 [PubMed]
• van Vollenhoven R. F. DHEA in systemic lupus erythematosus Rheumatic diseases clinics of North America 2000;26 (2):349-+ [PubMed]

1999

• van Vollenhoven R. F., Park J. L., Genovese M. C., West J. P., McGuire J. L. A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus Lupus 1999;8 (3):181-187 [PubMed]
• Sundaramurthy S. G., Karsevar M. P., van Vollenhoven R. F. Influence of hormonal events on disease expression in patients with the combination of systemic lupus erythematosus and rheumatoid arthritis Journal of clinical rheumatology 1999;5 (1):9-16 [PubMed]
• Ward M. M., Lotstein D. S., Bush T. M., Lambert R. E., van Vollenhoven R., Neuwelt C. M. Psychosocial correlates of morbidity in women with systemic lupus erythematosus Journal of rheumatology 1999;26 (10):2153-2158 [PubMed]
• van Vollenhoven R. F. Severe rheumatoid arthritis Journal of rheumatology 1999;26 (1):197 [PubMed]
• Engel G., van Vollenhoven R. F. Treatment of severe CNS lupus with intravenous immunoglobulin Journal of clinical rheumatology 1999;5 (4):228-232 [PubMed]
• van Vollenhoven R. F., Bieber M. M., Powell M. J., Gupta P. K., Bhat N. M., Richards K. L., Albano S. A., Teng N. N. VH4-34 encoded antibodies in systemic lupus erythematosus: A specific diagnostic marker that correlates with clinical disease characteristics Journal of rheumatology 1999;26 (8):1727-1733 [PubMed]

1998

• van Vollenhoven R. F. Corticosteroids in rheumatic disease - Understanding their effects is key to their use Postgraduate medicine 1998;103 (2):137-142 [PubMed]
• Barry N. N., McGuire J. L., van Vollenhoven R. F. Dehydroepiandrosterone in systemic lupus erythematosus: Relationship between dosage, serum levels, and clinical response Journal of rheumatology 1998;25 (12):2352-2356 [PubMed]
• Gremillion R. B., van Vollenhoven R. F. Rheumatoid arthritis - Designing and implementing a treatment plan Postgraduate medicine 1998;103 (2):103-+ [PubMed]
• van Vollenhoven R. F. Rheumatology in primary care - A five-article symposium Postgraduate medicine 1998;103 (2):67
• van Vollenhoven R. F. Role of sex steroids in the Th1/Th2 cytokine balance: comment on the article by Miossec and van den Berg Arthritis and rheumatism 1998;41 (10):1897-1898 [PubMed]
• Lotstein D. S., Ward M. M., Bush T. M., Lambert R. E., van Vollenhoven R., Neuwelt C. M. Socioeconomic status and health in women with systemic lupus erythematosus Journal of rheumatology 1998;25 (9):1720-1729 [PubMed]
• van Vollenhoven R. F., Morabito L. M., Engleman E. G., McGuire J. L. Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months Journal of rheumatology 1998;25 (2):285-289 [PubMed]

1997

• Lee Y. S., Schlotzhauer T., Ott S. M., van Vollenhoven R. F., Hunter J., Shapiro J., Marcus R., McGuire J. L. Skeletal status of men with early and late ankylosing spondylitis American journal of medicine 1997;103 (3):233-241 [PubMed]

1996

• van Vollenhoven R. F. Hormones and systemic lupus erythematosus Annales de médecine interne 1996;147 (4):239-240
• van Vollenhoven R. F., McGuire J. L. Studies of dehydroepiandrosterone (DHEA) as a therapeutic agent in systemic lupus erythematosus Annales de médecine interne 1996;147 (4):290-296 [PubMed]
• Druzin M. L., van Vollenhoven R. F. Systemic lupus erythematosus and pregnancy Annales de médecine interne 1996;147 (4):265-273 [PubMed]

1995

• van Vollenhoven R. F. Adhesion molecules, sex steroids, and the pathogenesis of vasculitis syndromes Current opinion in rheumatology 1995;7 (1):4-10 [PubMed]
• van Vollenhoven R. BREAST IMPLANTS AND CONNECTIVE-TISSUE DISEASES New England journal of medicine 1995;333 (21):1424 [PubMed]
• van Vollenhoven R. F., Engleman E. G., McGuire J. L. Dehydroepiandrosterone in systemic lupus erythematosus - Results of a double-blind, placebo-controlled, randomized clinical trial Arthritis and rheumatism 1995;38 (12):1826-1831 [PubMed]

1994

• van Vollenhoven R. F., Engleman E. G., McGuire J. L. AN OPEN STUDY OF DEHYDROEPIANDROSTERONE IN SYSTEMIC LUPUS-ERYTHEMATOSUS Arthritis and rheumatism 1994;37 (9):1305-1310 [PubMed]
• van Vollenhoven R. F., McGuire J. L. ESTROGEN, PROGESTERONE, AND TESTOSTERONE - CAN THEY BE USED TO TREAT AUTOIMMUNE-DISEASES Cleveland Clinic journal of medicine 1994;61 (4):276-284 [PubMed]

1990

• van Vollenhoven R. F., Thorbecke G. J., Siskind G. W. EXPOSURE OF FEMALE MICE TO TYPE-II COLLAGEN REDUCES SUSCEPTIBILITY TO COLLAGEN-INDUCED ARTHRITIS IN OFFSPRING European journal of immunology 1990;20 (9):2149-2152 [PubMed]

1989

• van Vollenhoven R. F., Swenson C. D., Soriano A., Goidl E. A., Coico R. F., Thorbecke G. J., Siskind G. W. SERUM IGD LEVELS IN MICE - EFFECT OF STRAIN, AGE AND AUTOIMMUNE-DISEASE Journal of autoimmunity 1989;2 (3):259-267 [PubMed]

1988

• Nagler-Anderson C., van Vollenhoven R. F., Gurish M. F., Bober L. A., Siskind G. W., Thorbecke G. J. A CROSS-REACTIVE IDIOTYPE ON ANTI-COLLAGEN ANTIBODIES IN COLLAGEN-INDUCED ARTHRITIS - IDENTIFICATION AND RELEVANCE TO DISEASE Cellular immunology 1988;113 (2):447-461 [PubMed]
• Swenson C. D., van Vollenhoven R. F., Xue B., Siskind G. W., Thorbecke G. J., Coico R. F. PHYSIOLOGY OF IGD .9. EFFECT OF IGD ON IMMUNOGLOBULIN PRODUCTION IN YOUNG AND OLD MICE European journal of immunology 1988;18 (1):13-20 [PubMed]
• van Vollenhoven R. F., Soriano A., McCarthy P. E., Schwartz R. L., Garbrecht F. C., Thorbecke G. J., Siskind G. W. THE ROLE OF IMMUNITY TO CARTILAGE PROTEOGLYCAN IN ADJUVANT ARTHRITIS - INTRAVENOUS-INJECTION OF BOVINE PROTEOGLYCAN ENHANCES ADJUVANT ARTHRITIS Journal of immunology (Baltimore, Md. 1988;141 (4):1168-1173 [PubMed]
• van Vollenhoven R. F., Nagler-Anderson C., Soriano A., Siskind G. W., Thorbecke G. J. TOLERANCE INDUCTION BY A POORLY ARTHRITOGENIC COLLAGEN-II CAN PREVENT COLLAGEN-INDUCED ARTHRITIS Cellular immunology 1988;115 (1):146-155 [PubMed]

1987

• van Vollenhoven R. F., Braver J. K., Francus T., Schwartz R. L., Thorbecke G. J., Siskind G. W. A SYNGENEIC MLR INDUCED INVIVO RESULTS IN T-CELL MEDIATED IMMUNE SUPPRESSION Cellular immunology 1987;106 (2):397-407 [PubMed]